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ABSTRACT 
 
 CD44 receptor isoforms containing exon v6 (CD44v6) have been implicated in 
many cancer associated processes including metastasis and exosome-mediated pre-
metastatic niche formation. CD44v6 is a co-receptor for human growth factor (HGF) and  
vascular endothelial growth factor (VEGF), together with c-Met and VEGF receptor 2, 
respectively. CD44v6 isoforms are expressed in cancer stem cells and (pre-)malignant 
gastric lesions. Therefore, CD44v6 has potential as a target for early cancer diagnosis 
and/or for therapeutic intervention.  
 Targeted therapy has been instrumental in the oncology clinic for several years 
now. Targeting specific molecules has helped to reduce patient side effects commonly 
associated with classic chemotherapy. These molecules are mostly of biological origin 
with monoclonal antibodies (mAbs) representing the largest fraction. Antibodies, with their 
high specificity and affinity, are nature’s molecular recognition machines designed to aid 
the immune system in destroying extracellular and intracellular threats. A mAb is a unique 
species of antibody with affinity to only one specific part of a target molecule. Genetic 
engineering and recombinant protein technologies are providing a wonderful alternative to 
animal-derived antibody sources and allowing for fully human constructs. Recombinant 
mAbs can also be constructed from their associated fragments/domains and (re-
)engineered with more desirable pharmacological qualities. Though, other biologics in 
targeted therapy can also be composed of amino acids (i.e. peptides or proteins) or 
nucleic acids (e.g. antisense oligonucleotides). Aptamers are an emerging, nucleic acid-
based technology with the potential for high specificity and affinity to a wide array of 
molecules with some advantages over the dominating class of antibodies.  
 Targeted drug delivery borrows from the targeted therapy concept but takes it one 
step further. Here, the aim is to drive a drug to the specific site of action with the help of a 
vehicle. The vehicle can be a biomolecule (e.g. antibody) that is specific to, for example, a 
cell surface receptor or extracellular matrix molecule, or the vehicle can be based on 
nanotechnology. Bioconjugates based on antibodies are now emerging in the clinic as 
viable and potentially powerful agents in targeted drug delivery.  
 Nanotechnology applied to medicine (nanomedicine) is being exploited in the 
treatment of cancer and beyond, mainly as carriers for the delivery of drugs and/or 
diagnostics. Nanoparticles (NPs) can enhance a drug’s pharmacology through 
mechanisms such as controlled release, a capacity to harbor a plethora of 
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therapeutic/diagnostic payloads, intracellular delivery, multi-functionality, and 
responsiveness to environmental stimuli. NPs can also be engineered to overcome 
biological barriers such as the mucosa. Additionally, NPs can be conjugated with ligands 
allowing for cell/tissue-specific targeting. Thus, targeted drug delivery with ligand-
decorated NPs offers an attractive strategy for the treatment and/or diagnosis of a wide 
range of human diseases including (metastatic) carcinoma. 
 The main goal of this thesis was to develop polymeric NPs that are decorated with 
a biologic-based ligand for targeting CD44v6-expressing human cells. The first task was 
to identify a novel RNA aptamer with high specificity and affinity to human CD44v6. The 
second task was to develop and characterize ligand-decorated, polymeric NPs that target 
human CD44v6. Ideally, the novel ligand identified in the first task would be used to 
decorate the NPs in the second task. 
 A novel RNA aptamer against human CD44v6, presented as a peptide or on the 
cell surface, was attempted to be identified through selected evolution of ligands by 
exponential enrichment (SELEX). Twelve rounds of peptide-based and seven rounds of 
cell-based SELEX were performed, and each output was quality controlled by 
spectrophotometry and gel electrophoresis. Various rounds of the peptide-based SELEX 
outputs were fluorescently-labelled and tested for binding to the CD44v6-derived peptide 
and to CD44v6-expressing cells. No CD44v6-specific enrichment was detected by either 
of the binding assays. A post-hoc assay that replicated the capture step of the peptide 
SELEX using a positive control anti-CD44v6 ligand failed suggesting that the SELEX 
protocol was compromised. Alternative methods, such as high-throughput sequencing and 
bioinformatics technologies, may be able to reveal sequence enrichment, but for now, a 
novel aptamer against human CD44v6 was not identified needing further inquiry. 
 Development of proof-of-concept NPs was attempted by exploiting AbD15179, a 
well-characterized, human recombinant Fab fragment with high specificity and affinity to 
human CD44v6 (v6 Fab). Initial studies using polystyrene latex microspheres 
(FluoSpheres®) had many problems with aggregation and demonstrated no specific 
binding to CD44v6-expressing cells. Though, secondary attempts at developing Fab-
decorated, poly(lactic-co-glycolic acid) (PLGA)-based NPs (v6 Fab-PLGA NPs) were 
successful. The v6 Fab-PLGA NPs displayed spherical morphology around 300 nm and 
negative charge. They strongly bound to a CD44v6-derived peptide and, more 
importantly, to cells that endogenously and exogenously express CD44v6, but not to non-
expressing cells and cells expressing the standard form of CD44. v6 Fab-PLGA NPs 
produced in 2% polyvinyl alcohol (PVA) were unable to bind to the cells, and NPs 
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produced in 2% Pluronic F127 demonstrated the highest binding compared to those 
produced in sodium cholate or Tween-80. Empty and paclitaxel-loaded v6 Fab-PLGA NPs 
had nominal cytotoxicity at 50 µg/mL. Lastly, v6 Fab-PLGA NPs resisted simulated 
intestinal fluid exposure and cryopreservation. 
 Overall, the thesis-related research achieved the overall goal of developing 
CD44v6-specific polymeric NPs. Although a novel ligand that is specific to human CD44v6 
was not identified; the second aim of developing a human compatible, polymeric 
nanocarrier that targets human CD44v6 was completely achieved. In their present form, 
the v6 Fab-PLGA NPs demonstrated favorable physicochemical, biological and 
technological qualities that allow them to potentially be used in the oncology clinic as an 
(in vivo) diagnostic tool. Though, their use in drug delivery requires further investigation 
and optimization. In conclusion, NPs targeting CD44v6 have potential as in vivo diagnostic 
agents and/or as anti-cancer drug delivery agents in patients previously stratified with 
CD44v6+ carcinomas. 
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RESUMO 
 
 As isoformas do receptor CD44 contendo o exão v6 (CD44v6) foram implicadas 
em muitos processos associados ao cancro, incluindo metástases e formação de nicho 
pré-metastático mediada por exossomos. O CD44v6 é um co-receptor para o fator de 
crescimento humano (HGF) e fator de crescimento endotelial vascular (VEGF), 
juntamente com o receptor c-Met e receptor VEGF 2, respectivamente. As isoformas de 
CD44v6 são expressas em células-tronco de câncer e lesões gástricas (pré-) malignas. 
Portanto, o CD44v6 tem potencial como alvo para o diagnóstico precoce do câncer e/ou 
para intervenção terapêutica. 
 Terapia direcionada tem sido fundamental na clínica oncológica há vários anos. A 
segmentação de moléculas específicas ajudou a reduzir os efeitos colaterais do paciente 
comumente associados à quimioterapia clássica. Estas moléculas são principalmente de 
origem biológica com anticorpos monoclonais (mAbs) representando a maior fração. 
Anticorpos, com sua alta especificidade e afinidade, são máquinas de reconhecimento 
molecular da natureza projetadas para ajudar o sistema imunológico a destruir ameaças 
extracelulares e intracelulares. Um mAb é uma espécie única de anticorpo com afinidade 
para apenas uma parte específica de uma molécula alvo. As tecnologias de engenharia 
genética e proteína recombinante estão fornecendo uma alternativa maravilhosa às 
fontes de anticorpos derivados de animais e permitindo construções totalmente humanas. 
Os mAbs recombinantes tambem podem ser construidos a partir dos seus 
fragmentos/dominios associados e (re-)manipulados com qualidades farmacolicas mais 
desejeis. No entanto, outros produtos biológicos na terapia alvo podem também ser 
compostos por aminoácidos (i.e. péptidos ou proteínas) ou ácidos nucleicos (por 
exemplo, oligonucleótidos antisense). Os aptâmeros são uma tecnologia emergente 
baseada em ácido nucléico, com o potencial de alta especificidade e afinidade para uma 
ampla gama de moléculas com algumas vantagens sobre a classe dominante de 
anticorpos. 
 A entrega direcionada de medicamentos toma emprestado do conceito de terapia 
direcionada, mas dá um passo adiante. Aqui, o objetivo é dirigir um medicamento para o 
local específico da ação com a ajuda de um veículo. O veículo pode ser uma biomolecula 
(por exemplo, anticorpo) que especica para, por exemplo, um receptor da superficie 
celular ou molecula da matriz extracelular, ou o veículo pode ser baseado em 
nanotecnologia. Os bioconjugados baseados em anticorpos estão agora surgindo na 
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clínica como agentes viáveis e potencialmente poderosos no fornecimento direcionado de 
drogas. 
 A nanotecnologia aplicada à medicina (nanomedicina) está sendo explorada no 
tratamento do câncer e além, principalmente como portadores para a entrega de 
medicamentos e/ou diagnósticos. As nanopartículas (NPs) podem melhorar a 
farmacologia de um medicamento por meio de mecanismos como liberação controlada, 
capacidade de abrigar uma infinidade de cargas terapêuticas/diagnósticas, entrega 
intracelular, multifuncionalidade e capacidade de resposta a estímulos ambientais. NPs 
também podem ser projetados para superar barreiras biológicas, como a mucosa. 
Adicionalmente, os NPs podem ser conjugados com ligandos, permitindo a segmentação 
específica de células/tecidos. Assim, a distribuio direccionada de farmacos com NPs 
decoradas com ligandos oferece uma estratia atractiva para o tratamento e/ou 
diagnostico de uma vasta gama de doencas humanas incluindo carcinoma (metastico). 
 O objetivo principal desta tese foi desenvolver NPs poliméricos que são 
decorados com um ligante biológico para o direcionamento de células humanas 
expressando CD44v6. A primeira tarefa foi identificar um novo aptâmero de RNA com alta 
especificidade e afinidade para o CD44v6 humano. A segunda tarefa foi desenvolver e 
caracterizar os NPs poliméricos, decorados com ligantes, que têm como alvo o CD44v6 
humano. Idealmente, o novo ligante identificado na primeira tarefa seria usado para 
decorar os NPs na segunda tarefa. 
 Um novo aptâmero de RNA contra CD44v6 humano, apresentado como um 
peptídeo ou na superfície celular, foi tentado para ser identificado através de evolução 
selecionada de ligantes por enriquecimento exponencial (SELEX). Foram realizadas doze 
rodadas de base de peptídeos e sete rodadas de SELEX baseado em células, e cada 
resultado foi controlado com qualidade por espectrofotometria e eletroforese em gel. 
Varios ciclos dos outputs de SELEX baseados em peptidos foram marcados de modo 
fluorescente e testados quanto ligacçao ao ptido derivado de CD44v6 e a culas que 
expressam CD44v6. Nenhum enriquecimento específico para CD44v6 foi detectado por 
qualquer um dos ensaios de ligação. Um ensaio post-hoc que replicou o passo de 
captura do péptido SELEX utilizando um ligando anti-CD44v6 de controlo positivo falhou 
sugerindo que o protocolo SELEX estava comprometido. Métodos alternativos, como o 
sequenciamento de alto rendimento e as tecnologias de bioinformática, podem revelar o 
enriquecimento da sequência, mas, por enquanto, um novo aptâmero contra o CD44v6 
humano foi identificado sem sucesso. 
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 O desenvolvimento de NPs de prova de conceito foi tentado explorando 
AbD15179, um fragmento Fab recombinante humano bem caracterizado com elevada 
especificidade e afinidade para CD44v6 humano (v6 Fab). Estudos iniciais utilizando 
microesferas de látex poliestireno (FluoSpheres®) tiveram muitos problemas com 
agregação e não demonstraram nenhuma ligação específica a células que expressam 
CD44v6. No entanto, tentativas secundárias de desenvolver NPs com base em poli (ácido 
láctico-co-glicólico) (PLGA) com decoração de Fab (v6 Fab-PLGA NPs) obtiveram 
sucesso. Os NPs v6 Fab-PLGA apresentaram morfologia esférica em torno de 300 nm e 
carga negativa. Ligam-se fortemente a um péptido derivado de CD44v6 e, mais 
importante, a células que expressam endogenamente e exogenamente CD44v6, mas não 
a células não expressantes e a células que expressam a forma padrão de CD44. As NPs 
de v6 Fab-PLGA produzidas em álcool polivinílico a 2% (PVA) foram incapazes de se 
ligar às células, e as NPs produzidas em Pluronic F127 a 2% demonstraram a maior 
ligação em comparação com as produzidas em colato de sódio ou Tween-80. Os v6 Fab-
PLGA NPs vazios e carregados com paclitaxel tinham citotoxicidade nominal a 50 µg/mL. 
Ultimamente, as v6 Fab-PLGA NPs resistiram a exposiçáo a fluido intestinal simulado e 
criopreserviçáo. 
 No geral, a pesquisa relacionada à tese alcançou o objetivo geral de desenvolver 
NPs poliméricos específicos para CD44v6. Embora um novo ligando específico para o 
CD44v6 humano não tenha sido identificado; o segundo objetivo de desenvolver um 
nanocarreador polimérico compatível com humanos que atinja o CD44v6 humano foi 
completamente alcançado. Na sua forma atual, os v6 Fab-PLGA NPs demonstraram 
qualidades físico-químicas, biológicas e tecnológicas favoráveis que permitem que eles 
sejam potencialmente usados na clínica de oncologia como uma ferramenta diagnóstica 
(in vivo). No entanto, seu uso na entrega de medicamentos requer mais investigação e 
otimização. Em conclusão, as NPs direcionadas para CD44v6 têm potencial como 
agentes de diagnóstico in vivo e/ou como agentes de liberação de drogas anticâncer em 
pacientes previamente estratificados com carcinomas CD44v6+. 
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ACRONYMNS AND ABBREVIATIONS 
AA Amino acid 
ABC Antibody-biologic conjugate 
AbD15179 Human, anti-human CD44v6 Fab 
ADC Antibody-drug conjugate 
ADCC Antibody-dependent cell-mediated cytotoxicity 
ADIN Antibody-dependent intracellular neutralization 
ANC Antibody-nanoparticle conjugate 
BSA Bovine serum albumin 
CD44 Cluster of differentiation 44 
CD44std Standard isoform of CD44  
CD44v Variant isoform of CD44 
CD44v6 Variant isoforms of CD44 containing exon v6 
CDC Complement-dependent cytotoxicity 
CDR Complementarity-determining region 
CDR H3 CDR 3 from the heavy chain 
CH Constant region of the heavy chain 
CL Constant region of the light chain 
CP Cytoplasmic portion of CD44 
CR-CSC Colorectal cancer stem cell 
CSC Cancer stem cell 
CTC Circulating tumor cell 
DCM Dichloromethane 
DDS Drug delivery system 
DLS Dynamic light scattering 
dox Doxirubicin 
EC50 Half maximal effective concentration 
ECM Extracellular matrix 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial-to-mesenchymal transition 
ePCR Emulsion PCR 
EPR Enhanced permeability and retention 
ERK Extracellular related kinase 
ERM Ezrin, radixin, moesin 
F127 Pluronic F127 (aka Poloxamer 407) 
Fab Fragment antigen binding 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
Fc Fragment crystallizable 
FcR Fc receptor 
FcRn Neonatal Fc receptor 
FcγR Fc gamma receptor 
FKR648 Fluorescent dye with emission at 648 nm 
FluoSpheres® Polystyrene latex microspheres at 200 nm with yellow/green 
fluorescence 
GC Gastric cancer 
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GFP Green fluorsecent protein 
GP202 Gastric cancer cell line endogenously expressing CD44v6 
HA Hyaluronic acid 
HER2 Human epidermal growth factor receptor 2 
HGF Hepatocyte growth factor 
HIV Human immunodeficiency virus 
HNSCC Head-and-neck squamous cell carcinoma 
HPLC High pressure liquid chromatography 
HRP Horse radish peroxidase 
HuCAL Human combinatorial antibody library 
ICAM-1 Intercellular adhesion molecule-1 
Ig Immunoglobulin 
IgG Immunoglobulin G 
LDA Laser Doppler anemometry 
mAb Monoclonal antibody 
Mal Maleimide 
MEK Mitogen-activated protein kinase kinase 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MKN74 Gastric cancer cell line that does not express CD44 
Na Chol Sodium cholate 
NaN3 Sodium azide 
NGS Next-generation sequencing 
NPs Nanoparticles 
OPN Osteopontin 
PBS Phosphate buffered solution 
PBST PBS + 0.1% Tween-20 
PCR Polymerase chain reaction 
PdI Polydispersity index 
PEG Polyethylene glycol 
PI3K Phosphoinositide 3-kinase 
PLGA Poly(lactic-co-glycolic acid) 
PTX Paclitaxel 
PVA Polyvinyl alcohol 
RT Room temperature 
scFv Single-chain variable fragment 
sdAb Single-domain antibody 
SDF Stromal-derived factor 
SELEX Systematic evolution of ligands by exponential enrichment 
SIF Simulated intestinal fluid 
siRNA Small interferring RNA 
SPR Surface plasmon resonance 
SMCC Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
SM(PEG)24 Sulfo-SMCC linker containing 24 polyethylene glycol chains  
T/E Trypsin/EDTA 
TAC Tumor-associated cell 
TB Tuberculosis 
TEM Transmission electron microscopy 
TM Transmembrane region of CD44 
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TRIM21 Tripartite motif-containing protein 21 
TCEP Tris(2-carboxyethyl)phosphine 
v6 Fab-PLGA NPs PLGA NPs tethered with the anti-CD44v6 Fab 
VEGF Vascular endothelial growth factor 
VEGFR-2 VEGF receptor 2 
VH Variable domain from the heavy chain 
VHH Hypervariable domain from heavy chain-only antibodies (camelids) 
VL Variable domain from the light chain 
VLP Virus-like particle 
VNAR Variable new antigen receptor (sharks) 
w/o/w Water-in-oil-in-water  
YSD Yeast surface display 
(-) Fab-PLGA NPs PLGA NPs tethered with the negative control Fab 
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1. CD44v6 biology and its role in carcinoma 
1.1. General biology and structure of CD44 and its variant isoforms 
 Cluster of differentiation 44 (CD44) is a transmembrane glycoprotein expressed on 
the surface of many types of cells. CD44 functions in cell-cell adhesion, cell 
communication and cell-extracellular matrix interactions [1], and it is considered a 
biomarker for (cancer) stem cells [2]. CD44 is also a receptor for the extracellular matrix 
(ECM) molecules hyaluronic acid (HA), osteopontin (OPN) and many others. A hallmark of 
the CD44 gene is its very high amount of alternative splicing (Figure 1) [3].  
 The CD44 gene is composed of a total of 20 different exons. The standard and 
smallest form of CD44 (CD44std) is composed of 10 exons, termed s1-s10, of which all 
CD44-associated gene products contain. Exons s1-s7 codes for the extracellular domain, 
exon s8 codes for the transmembrane region, and exons s9-s10 code for the C-terminal 
cytoplasmic tail. CD44std is ubiquitously-expressed on the membrane of most mammalian 
cells. It is best known as a receptor for hyaluronic acid (HA); however, it also contains 
binding domains for collagen, fibronectin, and CD62 [1]. 
 Variant isoforms of CD44 (CD44v) express one or more additional exons termed 
v1 through v10 in a wide array of flavors, and their expression is typically restricted to 
epithelial cells and carcinomas [1]. These variant exons can also be glycosylated and fall 
between exons s5 and s6 placing them close to the cell surface. All of the possible variant 
isoforms coupled with different glycosylation patterns results in hundreds of, if not more, 
different possible biomolecules generated from the one CD44 gene. Depending on which 
tissue it is expressed in, a given CD44v often plays a well-defined role. Variant isoforms of 
CD44 containing exon v6 (CD44v6) have received a significant amount of interest since 
the early 1990’s due to their role in cancer biology. 
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Figure 1. Structure of the CD44 gene and protein. a-b) CD44 is composed of 20 different 
exons that are subjected to intense alternative splicing. Ten are included in all isoforms 
(s1-s10; green bars) and make up the extracellular and transmembrane (TM) domains as 
well as the cytoplasmic portion (CP). b) Variant isoforms of CD44 (CD44v) contain one or 
more additional exons (v1-v10; red bars) that are spliced into the stalk domain (s5-s6) in a 
wide array of combinations. c) The resulting gene products also become heavily 
glycosylated (colored circles) leading to more isoform diversity. Used with permission from 
[1]. 
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1.2. CD44v6 biology 
 Clinical interest in CD44v6 began when Günthert and co (1991) demonstrated that 
rat pancreatic cancer cells expressing CD44v6 displayed a metastatic phenotype [4]. 
Additionally, non-metastatic cells forced to express CD44v6 took on a metastatic 
phenotype, and treatment of rats orthotopically expressing these cells with a CD44v6 
blocking antibody halted lymph node and lung metastases. This initiated several studies 
into exploring the biology of CD44v6 and its potential as a therapeutic target [5, 6] and as 
a prognostic marker [7] for cancer. Since then, much has been discovered in all of the 
above aspects of CD44v6. Here, it is important to reiterate that “CD44v6” refers to many 
different CD44 glycoproteins that contain exon v6 alone or in combination with other 
variant exons. 
 CD44v6 expression is mainly restricted to proliferative tissue such as the skin and 
intestine [6] but can also be found in the endothelium and activated lymphocytes [8]. 
Through direct interaction [9], CD44v6 is required for hepatocyte growth factor (HGF) 
activation [10] and internalization [11] of the essential receptor tyrosine kinase c-Met in 
epithelial [10] and endothelial [12] cells (Figure 2). c-Met induces proliferation, 
differentiation, migration, survival and branching morphogenesis, and its deregulation 
often results in cancer and metastasis [13]. Though, it has been shown that c-Met recruits 
intercellular adhesion molecule-1 (ICAM-1) to compensate for loss of CD44v6 [14]. 
CD44v6 is also a co-receptor, again through direct interaction [9], of vascular endothelial 
growth factor A (VEGF-A) along with VEGF receptor 2 (VEGFR-2) [12]. In both c-Met [10] 
and VEGFR-2 [12], signal propagation is mediated by the association of the cytoplasmic 
tail of CD44v6 with ezrin, radixin and moesin (ERM) proteins (Figure 2). This couples 
CD44v6 to the cytoskeleton to control endothelial cell migration, sprouting and tubule 
formation [12] as well as Ras, MEK and ERK activation [15]. Importantly, HGF-induced 
Ras signaling promotes CD44v6 alternative splicing which in turn sustains Ras signaling 
thus creating a positive feedback loop and stimulating cell cycle progression [16]. 
Although more is known, the biology of CD44v6 is extremely relevant in cancer as 
explained below. 
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Figure 2. CD44v6 and c-Met association. Hepatocyte growth factor (HGF) activation of c-
Met (Met) requires CD44v6. The signaling cascade is initiated with the binding of the 
cytoplasmic tail of CD44v6 to the assemble the ezrin, radixin and moesin (ERM) proteins 
and SRC for downstream Ras-ERK and PI3K-Akt activation important for cell proliferation. 
Used with permission from [1]. 
 
1.3. Role of CD44v6 in cancer 
 The role of CD44v6 in cancer was established with the first metastasis studies on 
rat pancreatic carcinoma cells [4]. Since then, the role of CD44v6 in cancers from other 
tissue types, as well as different cancer-related processes, has been investigated.  
 In order for metastases to form, the secondary tissue often first needs to be primed 
to be a conducive environment to receive the incoming tumor cells [17]. Among other 
ways, this pre-metastatic niche can be initiated by exosomes or extracellular vesicles 
secreted by tumor cells which carry specific biomolecules that act as messengers for 
tissue remodeling. Jung et al. (2009) demonstrated that exosomes from the same 
CD44v6+ rat pancreatic cancer cells used in the Günthert et al. (1991) [4] study strongly 
promote metastases in the lung and lymph nodes in vivo [18]. 
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 While investigating the splicing pattern of CD44 and more in normal stomach and 
gastric cancer (GC), da Cunha and colleagues (2010) showed that CD44v6 expression 
was nominal in histochemical staining of normal stomach but increased as the severity of 
GC increased (Figure 3) [19]. Additionally, expression of CD44v6 was inversely 
correlated with that of E-cadherin, which has a functional pivotal role in GC [20]. This 
supports the role of CD44v6 in the epithelial-to-mesenchymal transition (EMT) [21], an 
integral process in metastasis [22]. It was also shown that the highest levels of the 
CD44v6 transcript in a GC cell line panel was found in GP202 (relevant for the studies in 
Chapter IV).  
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Figure 3. Immunohistochemical staining of CD44v6 in patient-derived gastric (cancer) 
tissue. a) Normal stomach tissue expresses nominal levels of CD44v6. b) Low-to-
moderate levels of CD44v6 is observed in hyperplasia. CD44v6 expression increases as 
the severity of GC increases as seen in complete metaplasia (c) to incomplete metaplasia 
(d) with very high levels seen in low-grade (e) and high-grade (f) dysplasia. Adapted with 
permission from [19]. 
 
 Cancer stem cells (CSCs), also called cancer initiating cells, are a set of rare cells 
in a tumor that are, debatably, initiators and drivers of tumor growth and metastasis and 
resist conventional therapeutics [23, 24]. CD44 has been recognized as a CSC marker for 
many years now [1, 2]. Of course this biomarker assessment is dependent on antibody 
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staining. Though, given the extensive alternative splicing of CD44 and the antibody 
reliance, it seems probable that designating CD44 as a stem cell marker may be referring 
to CD44v and not CD44std. A thorough study clearly demonstrated that colorectal cancer 
stem cells (CR-CSCs) [25] express CD44v6 (Figure 4) [21]. CD44v6- progenitor cells do 
not lead to metastases; however, stimulation of these cells with the cytokines HGF, OPN 
and stromal-derived factor (SDF) that are secreted by cancer associated fibroblasts 
acquire CD44v6 expression and a metastatic capability. Inhibition of phosphatidylinositol 
3-kinase (PI3K), actively-targeted in cancer therapy [26] (Figure 2), lead to specific killing 
of CD44v6+ CR-CSCs and reduced metastatic growth. A parallel patient cohort study 
revealed that survivability was increased with low levels of CD44v6 in CRC. This work 
validated CD44v6 as a functional biomarker and a therapeutic target. Supporting the 
previous study, cultured circulating tumor cells (CTCs) derived from stage IV CRC 
patients were shown to express hallmarks of CR-CSC such as CD44v6 [27]. 
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Figure 4. All colorectal cancer stem cells (CSC) express CD44v6. CD44v6- tumor 
associated cells (TACs) when stimulated by hepatocyte growth factor (HGF), osteopontin 
(OPN) and stromal-derived factor (SDF) secreted by cancer-associated fibroblasts (CAFs) 
start to express CD44v6. CD44v6-expressing cells take on a CSC phenotype which 
includes migration and dispersal to secondary sites to initiate metastasis. Used with 
permission from [21]. 
 
1.4. CD44v6 as a prognostic marker or therapeutic/diagnostic target 
 Because CD44v6 is associated with metastasis, many studies mainly in the early 
2000’s looked into the prognostic value of CD44v6 expression [7, 28-31]. Unfortunately, 
the results were varied; though, most studies showed a positive correlation with Dukes 
stage and CD44v6 expression. It is probable that the mixed results were caused by a 
technical problem, such as antibody choice during immunohistochemical staining, and not 
a biological one. Though, the more recent Todaro et al. (2014) study cited above did 
demonstrate the prognostic value of CD44v6 in CRC [21]. 
 The therapeutic value of CD44v6 has also been investigated over the last few 
decades [6, 32, 33]. As mentioned above, the initial rat pancreatic carcinoma studies used 
an anti-CD44v6 mAb to block metastatic spread [4]. The first clinical therapeutic was an 
antibody-drug conjugate of the anti-CD44v6 monoclonal antibody, bivatuzumab coupled 
with the cytotoxic microtubule inhibitor mertansine [34, 35]. Two phase I trials were 
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conducted on patients with head and neck squamous cell carcinoma (HNSCC). Although 
it seems that the ADC had targeted the tumors in some of the patients, many of them 
developed skin rashes, exfoliation, or worse. One patient developed toxic epidermal 
necrolysis and died [34]. Most likely bivatuzumab mertansine targeted the skin 
keratinocytes causing the severe side effects. The use of this drug in the clinic was 
terminated due to the above toxicity reasons.  
 When Orian-Rousseau et al. (2002) identified that c-Met activation by HGF 
required presentation by CD44v6, they were able to inhibit that activation using mAbs 
directed towards specific CD44v6 epitopes [10]. Mutating three specific residues in the v6 
exon disrupted the c-Met co-receptor activation [36]. This work lead to the discovery of a 
five amino acid peptide containing these three residues that could also disrupt this 
activation. The same peptide could also disrupt VEGFR-2 binding thus providing a 
therapeutic to block angiogenesis in relevant pathologies [12]. Lastly, this peptide was 
able to inhibit tumor growth and metastasis in pancreatic cancer in vivo models [37]. It is 
important to note that, because this peptide is derived from the v6 exon, it does not bind to 
CD44v6 and functions by interfering with its co-receptor functions with c-Met and VEGFR-
2. Therefore, clinical studies should not see the same skin toxicities that were seen with 
bivatuzumab mertansine [34, 35] but still result in inhibiting tumor growth and/or 
metastasis. In fact, this drug (AMC303) is currently in Phase I/Ib clinical trials for the 
treatment of patients with solid tumors (ClinicalTrials.gov #NCT03009214). 
 CD44v6 may also be amenable to in vivo diagnostics of some or all of the cancers 
outlined above. Thus, the anti-human CD44v6 Fab, AbD15179, was developed and 
characterized with the intent to target a radionuclide to CD44v6-expressing HNSCC cells 
[38]. AbD15179 is a fully human, recombinant Fab (see section 3.1.2 for more information 
about this term) that was selected and screened from the HuCAL® PLATINUM library [39] 
(see section 3.1.3 for more information about these terms) against a peptide derived from 
the v6 exon (see Chapters III and IV for its application in this thesis), and it has a binding 
affinity around 5-50 µM depending on whether the antigen is a biomolecule or expressed 
on the cell surface. In vivo, radiolabeled AbD15179 demonstrated a moderate tumor-to-
organ ratio [40], and this Fab was further engineered as a F(ab’)2 for improved avidity and 
slower dissociation rate [41]. Given its specificity, affinity, fully human structure and in vivo 
targeting, AbD15179, or its derivative, has clinical potential to diagnose HNSCC or other 
CD44v6-expressing human cancers. 
 All of the above knowledge about the biology and 
therapeutic/diagnostic/prognostic value of CD44v6 makes it a prime candidate for the 
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targeted delivery of a drug and/or diagnostic for use in the oncology clinic. Specifically, 
one could inhibit metastases [4, 37] or could target CR-CSCs [21] or early-stage GC [19]. 
 
2. Nanomedicine and targeted drug delivery  
 Classic drugs in modern medicine are typically based on natural products derived 
from bacteria, plants or fungi. The active ingredient is often a purified small molecule 
frequently acting on the whole body. Depending on the mechanism of action and dose, 
these drugs may have (sometimes serious) side effects. As an example, 20th century 
chemotherapy drugs are active against proliferating cells which are good at targeting 
tumors that are growing out of control. However, they also kill other proliferating cells like 
blood cells, epithelial cells found in the stomach and intestine and hair follicles. Thus, 
there is a fine line between killing the tumor and killing the patient. 21st century medicines 
are a result of applying current technology with our vastly improved knowledge of 
genetics, molecular and cellular biology, biochemistry and materials science. 
 
2.1. General nanomedicine 
 Nanotechnology applications in medicine (nanomedicine) promise to greatly 
advance diagnosis and treatment of disease. Nanoparticles (NPs) are extremely versatile 
and can be engineered to display a multitude of pharmacological properties. In the context 
of drug delivery, nanotechnology is used to encapsulate the drug, or payload, for 
enhanced pharmacokinetics, bioavailability, and drug release to increase the therapeutic 
index by increasing efficacy and/or reducing side effects. As an example, Doxil is an 
approved nanomedicine that encapsulates doxorubicin (dox) within PEGylated liposomes 
[42]. Doxil is not more effective in reducing tumor volume; however, the nanoformulation 
helps to greatly reduce the cardiotoxicity common with free dox [43]. Importantly, 
nanoparticles can be engineered to overcome biological barriers [44] and target specific 
tissues or cells, enhancing drug delivery to its therapeutic destination. There are several 
NPs already in the clinic [45] with many more on the horizon. 
 Nanomedicine can impact a large spectrum of human diseases, including cancer 
[46], HIV [47] and TB [48], and can be engineered with many nanomaterials (Figure 5) to 
harbor many payload types (e.g. small to big (bio-)molecules). Small molecule drug 
candidates with high therapeutic potential often have poor solubility leading to poor 
bioavailability [49], and several formulation strategies exist to increase solubility (e.g. solid 
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dispersion [50] and nanoencapsulation [49]). Though biologics usually do not have 
solubility issues, they do face other problems associated with biology such as 
immunogenicity and difficulty to surpass biological barriers (e.g. gastrointestinal tract). 
Nanovaccines have also been developed for immunotherapy of cancer and beyond [51]. 
Administration of photosensitizers [52] and multiple therapeutics [53] is also possible with 
NPs. Beyond drug delivery, NPs can be used in in vivo diagnostics either as contrast 
agents themselves (e.g. quantum dots or gold NPs) or harboring them as payloads [54]. 
 
 
Figure 5. Illustration of the different materials and resulting nanoscale carriers that are 
found in current nanomedicine. Taken from the British Society for Nanomedicine website: 
www.britishsocietynanomedicine.org. 
 
 The lifespan of a biopharmaceutical is severely dependent on the mode of 
administration. For example, insulin is mainly administered by painful injection. Patients 
prefer to take drugs by less invasive means (e.g. mucosal); however, most 
biopharmaceuticals do not bode well in these environments. Nanotechnology is currently 
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being exploited for systemic drug delivery by non-parenteral routes [55]. The 
Nanomedicines and Translational Drug Delivery Group has extensive experience in the 
nanoencapsulation of macromolecular biotherapeutics based on proteins (e.g. insulin 
[56]), peptides (glucagon-like peptide [57]) and nucleic acids (e.g. siRNA [58]). 
 
2.2. General targeted drug delivery 
 Having a drug work at a specific site of action (e.g. tumor) while avoiding normal 
host tissue has many benefits for the patient such as reduction of side effects and greater 
therapeutic index. This “targeted therapy” has seen tremendous strides in the clinic 
impacting many disease indications, but none more so than cancer [59]. Here, the aim is 
to have the drug target a specific biomolecule that is in circulation or on the surface of, or 
within, a cell.  
 Two examples of blockbuster drugs demonstrating this targeted therapy in cancer 
treatment are bevacizumab and cetuximab. Bevacizumab is a mAb that blocks 
angiogenesis by inhibiting VEGF-A, an extracellular molecule [60, 61]. Because most solid 
tumors rely on increased angiogenesis to help supply nutrients, bevacizumab essentially 
starves the tumors and increases patient survival. Cetuximab is a mAb that binds and 
blocks epidermal growth factor receptor (EGFR), a cell surface receptor, for the treatment 
of metastatic cancer [62, 63]. Both targeted therapy agents can also be used in 
combination with traditional cancer therapy for enhanced efficacy (e.g. [64]). 
 Targeted drug delivery borrows from the targeted therapy concept but takes it one 
step further [65]. Here, the aim is to drive a drug to the specific site of action with the help 
of a vehicle. The vehicle can be a biomolecule (e.g. antibody) that is specific to, for 
example, a cell surface receptor or extracellular matrix molecule, or the vehicle can be 
based on nanotechnology (see below). Some of the best drugs that have been discovered 
also have tremendous side effects to the patient due to undesirable impact to the 
remaining host tissues thus negating their use in the clinic. Implementing the concepts of 
targeted drug delivery could enable these drugs to have clinical utility just by 
concentrating their activity at the site of action and reducing normal host tissue exposure. 
Designing novel systems always needs to take into account the properties and potential 
side effects of the drug, route of administration, the intended site of action and the disease 
indication.  
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2.3. Combining targeted drug delivery and nanomedicine 
 Targeted drug delivery and nanomedicine are now close friends [66]. One helps 
make up for where the other might be lacking. Targeted drug delivery systems (DDSs) 
can greatly increase the type, capacity and protection of their payload (e.g. cytotoxic drug) 
through the use of NPs. Nanomedicine can achieve greater localization to the site of 
action with the use of targeting agents (e.g. antibodies). Targeted nanomedicines can be 
decorated with a plethora of surface ligand types. These targeting agents are often 
composed of small molecules [67], nucleic acids (e.g. aptamers [68] (see Chapter III for 
many more details) or amino acids (i.e. peptides/proteins). However, antibodies are 
probably the most commonly-used ligand type to decorate NPs due to their high 
specificity, affinity and availability to a vast swath of molecules (see section 3.1.1), their 
ability to function as fragments (see section 3.1.2), their robust discovery technologies 
(see section 3.1.3) and their capacity for engineering (see section 3.1.4) to accommodate 
the demands of the developer.  
 Targeted DDSs based on nanotechnology come in two flavors (Figure 6) [65]. 
“Passive” DDSs are successful due in part to their circulation times. Use of stealth agents 
(e.g. polyethylene glycol (PEG)) help to reduce phagocytic uptake to help the drug bypass 
elimination machinery. Another example in tumor therapy is the exploitation of the 
enhanced permeability and retention (EPR) effect to concentrate the drug in the tumor. 
Though, years of research have concluded that the EPR effect is prominent in rodent 
models but highly heterogenous in human tumors [69, 70] and should be determined prior 
to administration of nanomedicines in the clinic [71]. “Active” DDSs use ligands to a 
specific molecule (e.g. antibodies) to concentrate the drug to the site of action (e.g. 
tumor). See section 4 for full details on these and other technologies currently found in 
targeted drug delivery. 
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Figure 6. Schematic of “passive” (via enhanced permeability and retention (EPR) effect) 
and “active” targeted drug delivery for the treatment of solid tumors. Used with permission 
from [72]. 
 
 The studies in Chapter IV were designed on the aforementioned qualities 
associated with targeted DDSs and NPs for the treatment/diagnosis of gastrointestinal 
tract cancers. 
 
3. Ligands used in targeted therapy 
3.1. Monoclonal antibodies (mAbs) 
 To better understand how monoclonal antibodies (mAbs) can be utilized in the 
targeted DDSs detailed below, it is first necessary to introduce  basic antibody biology. 
Once the biology has been established, the technologies used to discover novel 
antibodies and how they can be further engineered are presented.  
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3.1.1. Antibody biology 
 The core antibody, or immunoglobulin (Ig), structure is composed of a few 
domains/regions with their own unique role in the adaptive immunity process (Figure 7a) 
[73]. Ig contains two heavy (H) chains and two light (L) chains that are further subdivided 
into the constant (CH/CL) and variable (VH/VL) domains, and the overall structure is 
stabilized by interspersed disulfide bridges. Two fragment antigen-binding (Fab) regions 
are connected by a flexible hinge to one fragment crystallizable (Fc) region. One Fab 
expresses six complementarity determining regions (CDRs), three from each of the VH/VL 
domains, which are responsible for direct physical interaction with the target antigen (i.e. 
immune-stimulating molecule) and dictate binding affinity. The third CDR from the heavy 
chain (CDR H3) is particularly important. The glycosylated Fc, entirely composed of 
constant domains, is responsible for communication with the immune system through 
binding to various Fc receptors (FcRs). Fc is also necessary for the long circulation times 
of IgG, the most common Ig isotype, due to lysosomal degradation escape mediated by 
the neonatal Fc receptor (FcRn). FcRn also aids in the transfer of maternal IgG across the 
placental and intestinal barriers to the fetus and neonate, respectively [74, 75].  
 
Figure 7. The structural components of (a) a whole monoclonal antibody (mAb)/IgG 
include the fragment antigen-binding (Fab) and fragment crystallizable (Fc) regions that 
are composed of the constant (CH and CL) and variable (VH and VL) domains each 
containing a disulfide bridge (yellow curves). Direct antigen binding to the target antigen is 
made through the complementarity determining regions (CDRs) of the Fab fragment and 
immune effector function is mediated by the Fc fragment. (b) The most common antibody 
fragment derivatives are: F(ab’)2, Fab, single chain variable fragment (scFv) and single-
domain antibodies (sdAbs) from llamas (VHH), sharks (VNAR) or other species. 
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 Antibodies identify and destroy the vast array of pathogens (e.g. viruses, bacteria 
and diseased host cells) in several ways. Outside the cell, they can simply disrupt cellular 
entry or recruit the help of FcR-expressing immune effector cells mainly through antibody-
dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity 
(CDC) [76]. Inside the cell, antibody-coated pathogens are recognized by tripartite motif-
containing protein 21 (TRIM21) [77], a high affinity cytosolic FcR [78], which recruits the 
proteasome through auto-ubiquitination for pathogen degradation to prevent fatal infection 
[79]. This immune mechanism is termed antibody-dependent intracellular neutralization 
(ADIN) [80]. The plethora of pathogens/antigens one can encounter necessitates an on-
demand, diverse antibody repertoire (~1012 possible unique antibody sequences) made 
possible by V(D)J recombination of only three Ig genes [81]. 
 
3.1.2. Antibody fragments 
 Targeted DDSs with mAbs relies only on the antigen-binding variable domains and 
can dispense with the Fc, as long as FcR-dependent effector function is not a 
consideration. Many antibody fragment-based formats exist that mainly revolve around the 
VH/VL domains [82]. The most common ones are the single-chain variable fragment 
(scFv), Fab and F(ab’)2 (Figure 7b). Their smaller size is advantageous, because they 
are easier to produce by recombinant protein expression, which is useful during selections 
and screens (see section 3.1.3), and it helps to reduce the overall size of the downstream 
nanocarrier. 
 Interestingly, camelids [83] and some sharks [84] express heavy-chain only 
antibodies, making it possible to isolate the VH domain as VHH (i.e. nanobody) and VNAR, 
respectively. It is also possible to isolate the VH or VL domains from normal antibodies, 
and all these formats are considered as single-domain antibodies (sdAbs) (Figure 7b).  
 
3.1.3. Antibody discovery 
 The original technology to create mAbs started by fusing myeloma cells (B cell 
cancer) with spleen cells from sero-positive mice immunized with the target antigen 
resulting in hybridoma cells that are both immortal and secrete the antibody of interest 
[85]. As the gene can be sequenced from a single clone, genotype can then be linked to 
phenotype. 
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 The true power of mAbs was unleashed in the late 1980’s when the genes 
encoding the variable domains extracted from a population of B cells (i.e. antibody library) 
were able to be cloned [86, 87], recombinantly-expressed [88], and in vitro displayed [89]. 
Depending on their source of origin, antibody libraries come in several flavors: naïve, 
immune, semi-synthetic or fully synthetic. Importantly, the functional diversity of an 
animal-derived library is typically 107-8. Fully synthetic libraries are designed and 
constructed to include synthetic genes derived from known (human) antibody frameworks 
with the capacity to generate a large diversity in appropriate regions, such as CDRs [90]. 
The HuCAL® (Human Combinatorial Antibody Library) [91] library was a first generation 
synthetic library consisting of 1010 fully human Fab fragments with further improvements 
from the GOLD® [92] and second generation PLATINUM® [39] versions. The anti-human 
CD44v6 Fab in Chapter IV was, in fact, derived from the HuCAL PLATINUM® library. 
 Enrichment of target-specific affinity binders is possible through a process of 
selection [93-95], and in a way mimics the in vivo immune selection process [96] (Figure 
8). Briefly, the displayed library of antibodies is incubated in the presence of the target 
antigen. After removal of non-binders, the remaining antigen-bound clones are subjected 
to subsequent amplification. This “biopanning” is repeated several times to generate an 
enriched, yet still polyclonal, pool of binders. Finally, single clones are isolated and 
individually screened for reduction to a lead panel and further characterization. The 
selection and screening of recombinant antibodies process can be tailored to help 
maximize the amount of potential high affinity molecules, and many different strategies 
exist for antigen presentation, library construction, selection and screening, species cross-
reactivity and automation [97]. 
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Figure 8. Schematic depicting the early stages of the general antibody discovery process 
and the emerging technologies that aim to improve each step of the process. Once a 
target molecule (e.g. cell surface receptor) is defined, an immunoglobulin (Ig)-producing 
animal (e.g. mouse) is immunized with the target antigen (e.g. peptide) to initiate the 
antibody response. The variable genes (VH/VL) are then isolated from the antibody-
producing B cells of positive responders, and polyclonal libraries, often in the single-chain 
variable fragment (scFv) format, are constructed and packaged into the one of the many 
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in vitro display technologies (e.g. phage). The displayed libraries are then selected 
(polyclonal) and screened (monoclonal) for binding to the target antigen. Positive binders 
are sequenced, recloned, purified and further characterized in functional assays on cells 
and in animal models. Improvements in the discovery process that have emerged are the 
use of: DNA vaccines and virus-like particles (VLPs) to enhance immunogenicity, 
alternative animals to increase repertoire diversity, fully synthetic libraries (e.g. HuCAL®) 
to eliminate the need for immunized animals, mammalian cell display to have more native 
presentation, cell-free display and in silico analysis coupled with high-throughput 
technologies (e.g. next generation sequencing (NGS)) to decrease discovery time and, 
lastly, autocrine-based selection systems to bypass the target binding process and directly 
select for antibodies with a defined functional phenotype. Figure not drawn to scale. 
 
 In vitro display technologies opened up a whole new realm of possibilities in 
antibody/protein discovery and engineering. A handful of different display technologies 
used in the discovery process are following (Table 1). Phage display technology [98] 
allows a foreign gene to be inserted within a filamentous bacteriophage coat protein for 
display on the virion surface while still retaining infectivity [99]. In this genotype-to-
phenotype format, the entire repertoire of variable or Fab fragment genes, from mice [89] 
and humans [96, 100] for example, can be packaged into the phage as a library, and 
library sizes can be quite large (>1010). Yeast surface display (YSD) is the most popular 
display method after phage display [101]. Here, a library of antibody fragments (e.g. scFv) 
are expressed on the surface of yeast cells and selected for target binding through 
successive rounds of mutagenesis and fluorescence-activated cell sorting (FACS) 
selection [102, 103]. An advantage of YSD is the eukaryotic post-translational processing 
of secreted proteins (e.g. glycosylation [104]). Mammalian virus/cell surface display 
systems have begun to offer some advantages in mAb discovery where FACS is also 
used [105, 106]. Recently, an elegant system whereby candidate antibodies are selected 
based on a designated phenotypic output was developed [107, 108]. Updated versions of 
this autocrine-based selection system incorporated a reporter construct and FACS for 
selection [109] and later anchored the antibody to a membrane protein to maintain 
receptor co-localization [110, 111]. Intracellular antibodies can also be functionally 
selected as seen by survival of cell death induced by rhinovirus [112]. Some 
display/protein synthesis systems eliminate the cell altogether [113] and have been 
applied to mAb production [114]. These cell-free systems display the antibody on a 
ribosome [115] or mRNA [116, 117], usually as an scFv or Fab [118] in translation 
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systems mainly based on E. coli [119], wheat germ, rabbit reticulocyte [120] or insect cell 
[121] lysates.  
 
Table 1. Novel mAbs can be identified using any of the different in vitro display 
technologies listed here. As with any technology, there are advantages and 
disadvantages to each. Selected references are presented that provide more details 
and/or demonstrate the power of each technology. 
Display 
technology 
Advantages Disadvantages 
Selected 
references 
Phage/ 
bacteria 
•Established 
•Successful 
•Robust 
•Prokaryotic translation 
•µM affinity  
[89], [98], 
[122] 
Yeast 
surface 
•Eukaryotic translation 
•Established 
•FACS selection 
•Limited library sizes 
[101, 102], 
[123] 
Mammalian 
virus/cell 
•Mammalian translation 
•Full length IgG possible 
•FACS selection 
•Accounts for downstream 
manufacturing 
•Emerging, thus not 
established 
•Specialized 
 
[105, 106, 
124] 
Autocrine 
•Selections based on a functional 
phenotype 
•Unnecessary prior target 
knowledge 
•Specialized 
•Patent protected [107], [111, 
112] 
Cell-free 
•Rapid 
•Ability to incorporate unnatural 
amino acids 
•Ability to couple to microfluidics 
•No post-translational 
modifications [114, 115, 
125] 
 
3.1.4. Antibody engineering 
 Once a lead candidate is identified that binds to a specific target by one or more of 
the means detailed above, it can be further engineered for enhanced pharmacology and 
beyond due to their recombinant nature. Many strategies can improve antibody 
pharmacokinetics/dynamics in humans (Figure 9). Chimerization/humanization aims to 
lower immunogenicity by replacing the non-antigen binding parts of the antibody that were 
derived from another animal source with human versions [126]. Affinity maturation aims to 
increase the affinity of the mAb by selecting and screening for mutants of the original lead 
mAb with higher binding to the target [127]. Fc modification aims to enhance immune 
effector function or circulation times by increased engagement with Fcγ receptors [128] or 
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FcRn [74], respectively. Engineering strategies aimed at improving stability and 
aggregation are mostly a manufacturing and storage concern that conveniently results in 
lowered immunogenicity [129]. Some of the above strategies can also be aided by 
computational tools. 
 
 
Figure 9. Engineering mAbs for enhanced pharmacology and storage are possible with 
several strategies. Chimerization and humanization aim to reduce immunogenicity 
associated with mAbs originating from non-human sources by replacing the constant 
domains or the entire mAb scaffold with human versions, respectively. Increasing the 
binding kinetics of a mAb is driven by in vitro affinity maturation strategies focusing on 
point mutations, usually within the complementarity determining regions (CDRs), which 
often replace uncharged amino acids (AAs) with charged ones to increase electrostatic 
interactions. Immune effector function is enhanced by modifying Fc with engineered 
glycosylation groups or with specific AA mutations for increased binding to Fcγ receptor 
(FcγR) III and decreased binding to FcγRIIB. Circulation times can be extended with AA 
mutations that enhance binding of Fc to the neonatal Fc receptor (FcRn). Long-term 
storage of mAbs can lead to instability and/or aggregation that often cause increased 
immunogenicity. This can be overcome through simple formulation adjustment or by 
incorporating specific point mutations, an additional intra-domain disulfide bridge between 
the CH2 and CH3 domains, an altered disulfide bond network within the Fab and/or a 
charged fusion tag. 
 
3.2 Aptamers and SELEX 
 Nucleic acid-based aptamers (single-stranded DNA or RNA) are an alternative and 
emerging class of molecules [130] that can act as therapeutics alone [131] or as targeting 
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ligands [132, 133] (Figure 10). Aptamers are functionally similar to antibodies but present 
some added advantages such as smaller size, easier production and modification, 
desirable storage properties, nominal immunogenicity, and the ability to conjugate to 
biomolecules/nanoparticles [131]. 
 
 
Figure 10. Schematic diagram of an aptamer binding to its target. The sequence of the 
aptamer defines its three-dimensional conformation that is based on areas of base-pairing 
and non-pairing. Used with permission from [134] 
 
 The aptamer discovery process is relatively similar to the antibody discovery 
process. For both antibodies and aptamers, novel ligand identification occurs through a 
repetitive enrichment process of incubating a very large and diverse polyclonal pool of 
potential ligands on a pre-defined target (e.g. receptor), removing unbound/non-specific 
ligands, amplifying the target-specific ligands and repeating the process over several 
cycles.  
 Novel aptamers are identified through a process termed selected evolution of 
ligands by exponential enrichment (SELEX) (Figure 10) [135, 136]. Basically, the process 
starts with incubating a synthetic polyclonal library with the target. The target, for example 
a cell surface receptor like CD44v6, can be presented in a number of ways such as a 
peptide, a recombinant or purified protein, or on the surface of a cell. Each target 
presentation has advantages and disadvantages. Once specific aptamers bind to the 
target, unbound aptamers are washed away. Target-specific aptamers are then amplified 
by the polymerase chain reaction (PCR). This process is then repeated for several cycles, 
typically 8-20 cycles. Assuming the SELEX process was successful, we end with an 
enriched polyclonal pool of aptamers with varying affinities and specificities to the target. 
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Individual clones are then sequenced, synthesized and characterized for their affinity and 
specificity to the target. Unlike antibody discovery that typically need 2-3 rounds of 
selection, one drawback of aptamer discovery is that many more rounds of SELEX need 
to be performed before one is able to test for target enrichment. 
 
 
Figure 10. Schematic depicting the systematic evolution of ligands by exponential 
enrichment (SELEX) procedure. Briefly, a library of ~1014 short, single-stranded 
DNA/RNA-based oligonucleotides (aptamers) is incubated with the target molecule. 
Unbound aptamers are washed away and bound aptamers are converted to a double-
stranded DNA by polymerase chain reaction (PCR) for amplification. The dsDNA is then 
converted back to the original ssDNA/RNA format ready for another round of selection. 
This process is then repeated for several more cycles to enrich for target-specific 
aptamers. Poly- or monoclonal aptamers are then sequenced and screened for binding to 
the target ready for downstream applications. Used with permission from [136]. 
 
 The above SELEX description is a very simplified version of the overall procedure. 
Importantly, SELEX is very malleable and can, and needs to, be adjusted according to the 
oligonucleotide composition (i.e. DNA or RNA) and/or the target molecule type (e.g. 
peptide or cell) [137]. For example, when identifying RNA-based aptamers, two extra 
steps of converting the RNA to DNA for PCR amplification and back to RNA are 
necessary, because PCR is limited to DNA only. Recently, high throughput sequencing 
and bioinformatics technologies have been implemented to allow for sophisticated 
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protocols that can reduce cycle number, and ultimately discovery time, as well as 
identification of rare binders not detected with traditional methods (e.g. [138, 139]).  
 
4. Antibody-decorated nanoparticles 
 Targeted therapy of cancer with mAbs holds tremendous promise in the specific 
elimination of tumor cells without the systemic toxicity associated with conventional 
chemotherapeutic agents (e.g. rituximab and B cell lymphomas). Unfortunately, only 
modest success has been achieved in patients with solid tumors, as the immunological 
mechanisms associated with tumor cell elimination have not proven to be as effective as 
expected [140]. To address this, several technologies have been developed that combine 
the specificity and affinity of antibodies with other drugs based on small molecules 
(antibody-drug conjugates (ADCs)) or biologics (antibody-biologic conjugates (ABCs)) or 
nanocarriers (antibody-nanoparticle conjugates (ANCs)). In the context of this thesis (see 
Chapter IV), an introduction to ANCs is presented below. 
 The early NP-based cancer therapeutics (e.g. Doxil) focused on “passive 
targeting” to tumors by avoiding the reticuloendothelial system and exploiting the 
enhanced permeability and retention effect, a consequence of leaky tumor vasculature 
[66, 141]. However, a major goal for nanomedicine is to drive the therapeutic directly to 
the site of action (e.g. receptor-overexpressing tumor cell) through decoration with ligands 
that bind to a specific target molecule (e.g. receptor), often termed “active targeting” [66]. 
Although no targeted NPs have been approved yet, close to 20 are in clinical trials. BIND-
014, one example that completed phase II trials for the treatment of prostate and lung 
cancer, is a PEGylated polymeric NP harboring docetaxol and decorated with a small 
molecule specific to prostate-specific membrane antigen [142]. Given the vast multitude of 
targeting ligands, drugs and nanomaterials, the possible combinations of the three are 
boundless. 
 Many factors contribute to the overall success or failure of targeted NPs including: 
a) route of administration, b) biological barriers [44], c) adsorption of host proteins to the 
NP surface [143], d) conjugation chemistry, e) hydrophobicity of the NP, f) composition, 
size, shape and charge of both the ligand and NP, g) density and orientation of the 
conjugated ligand [66] and h) ligand affinity/avidity (Figure 11). Additionally, the properties 
of the drug to be incorporated will dictate the method of nanoencapsulation. Antibodies 
serve as ideal targeting ligands for their affinity, specificity and engineering malleability 
[144].  
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Figure 11. Many factors dictate the in vivo behavior of ligand-decorated nanoparticles 
(NPs) including those associated with the nanoparticle (NP; left) as well as the ligand 
(right). The specific NP qualities to keep in mind are size, shape, charge and 
hydrophobicity, and these properties can also dictate the amount and composition of the 
protein corona. The specific ligand (i.e. mAb) qualities to consider are size and affinity, as 
well as density and orientation when coupled to the NP. Drawings are not to scale. 
Inspired by [66]. 
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 Active targeting of nanocarriers is possible through decoration with ligands, and 
antibodies or associated fragments have been proven to be quite viable for this purpose 
(Figure 12) [66]. These systems are often designed to target cell surface receptors and 
degrade and release their payload once the NPs enter the cell by a number of means. 
Fortunately, it seems that P-glycoprotein does not recognize the NPs, thus resulting in 
enhanced intracellular accumulation and nominal drug resistance [145]. 
 
 
Figure 12. The advantages and disadvantages of antibodies and nanoparticles 
demonstrating how the two systems can complement each other to further increase their 
therapeutic efficacy. Used with permission from [145]. 
 
 Early studies with targeted NPs focused on encapsulating classic chemotherapy 
agents to increase therapeutic index, mainly by lowering systemic toxicity. Park and 
colleagues demonstrated that immunoliposomes harboring dox and decorated with anti-
HER2 (Fab or scFv) had more tumor targeting efficacy and lower toxicity than all the other 
control treatments [146]. 
 Unlike ADCs and ABCs, the antibody (~10-20 nm) in this case is usually much 
smaller than the conjugated NP “cargo” (~100 nm), opening the possibility to attach many 
antibodies to a single NP. Similar to natural and bispecific antibodies, avidity may be 
exploited to enhance overall binding and/or specificity to the target antigen(s). A site-
specific conjugation strategy using expressed protein ligation and copper-free click 
chemistry was used to decorate anti-HER2 affibodies to superparamagnetic iron oxide 
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NPs at controlled ligand densities [147]. In fact, intermediate ligand density resulted in the 
highest cell binding, and this was confirmed with an alternative (non-antibody) ligand. 
Thus, optimal ligand density must be empirically determined for highest efficacy.  
 Ligand orientation on the NP can also affect antigen binding. Conventional 
chemistries do not afford control of where on the mAb (e.g. amines) the conjugation 
bridge is formed [148]. This leads to non-ideal conditions where many of the antibodies 
may be oriented on the NP such that the antigen-binding domains are unavailable for 
direct antigen contact. Engineering and recombinant strategies can overcome this 
disorientation and maximize antibody functionality. Whole IgG can be coupled to gold NPs 
through the Fc domain with the heterobifunctional linker, hydrazide-polyethylene glycol-
dithiol [149]. Another example is to engineer a Fab with a C-terminal cysteine and use a 
maleimide-based linker (e.g. succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (SMCC)) to couple to amine groups commonly found on various 
nanomaterials (e.g. chitosan [150]). This was the strategy used in a part of this thesis 
research (see Chapter IV).  
 In vivo diagnostics can also benefit from targeted NPs. Anti-EGFR-coated gold 
NPs were developed to aid in endoscopic tumor imaging [151]. Furthermore, combining a 
diagnostic agent along with the therapeutic payload (i.e. theranostic) offers the advantage 
of monitoring a treatment regimen during NP administration [152]. It should be noted 
though that more complexity added to a nanocarrier imposes greater cost (e.g. 
regulatory); thus, the trade-off should be considered before embarking on (pre-)clinical 
studies [153].  
 Although the overall strategy of “active targeting” has been criticized, highlighting 
the dearth of clinical evidence [154], the current literature points to the extreme validity of 
this strategy. Yet, clearly more research efforts must be dedicated into ways to identify 
and overcome the biological barriers inhibiting the targeting [44]. For example, the protein 
corona [155] is a well-characterized phenomenon known to disrupt targeting [156]. When 
in biological fluids (e.g. serum), biomolecules adsorb as a “hard” or “soft” layer onto the 
NP surface. The composition of this corona is dependent on the biological environment 
but also on the NP qualities (size, shape, charge, hydrophobicity, etc) [143]. These 
proteins can thus mask the ligand overriding any targeting capabilities, as seen in 
transferrin-coated NPs [156]. One way to overcome the inhibitory effects of the protein 
corona is through backfilling with PEG once the ligand has been conjugated to the NP 
[157]. 
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 The infinite combinations of drugs, ligands/antibodies, nanomaterials, 
encapsulation and conjugation methods and specific disease indications can frustrate the 
initial planning stages. On one hand, making decisions about the ideal system is quite 
challenging, but, on the other hand, these technologies can bring unprecedented 
possibilities. Regardless, the antibody-decorated nanocarrier platform is emerging as a 
highly promising tool in targeted drug delivery. 
 This chapter has set the stage for the basis of the research associated with this 
thesis. Section 1 demonstrated that CD44v6 is a valid therapeutic/diagnostic target for 
gastrointestinal cancers. Section 2 demonstrated that combining targeted drug delivery 
with nanomedicine currently offers the most promising strategy for driving a 
therapeutic/diagnostic to CD44v6-expressing cancers. Section 3 introduced two types of 
ligands, antibodies and aptamers, that are very promising as NP decorating agents for 
targeted drug delivery. This section discussed a bit of their structure and function as well 
as their methods of identification. Section 4 expanded on the use of antibodies as ligands 
for targeted NPs, a major theme of this thesis.  
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Aims of the thesis 
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 The overall aim of this doctoral thesis was to develop and characterize NPs able to 
delivering a drug and/or diagnostic agent to human cells/tissues that express CD44v6, 
while minimizing recognition of normal (non-CD44v6-expressing) cells/tissues. The 
downstream application of these NPs was intended to be for the treatment and/or 
diagnosis of gastrointestinal tract-related cancers that express CD44v6. 
The specific objectives of this research were: 
i) To identify a novel RNA aptamer specific to human CD44v6 by SELEX and to 
characterize that aptamer in biochemical and cell-based experiments (Chapter 
III).  
ii) To conjugate the novel ligand identified in Chapter III, or an established anti-
CD44v6 ligand as proof-of-principle, to polymeric NPs and characterize their 
physicochemical qualities such as size, polydispersity index, zeta-potential and 
morphology (Chapter IV). 
iii) To biologically characterize the developed NPs for binding specificity and 
affinity to CD44v6 presented as a biomolecule and on the surface of a cell as 
well as cell internalization and cytotoxicity (Chapter IV). 
iv) To technologically characterize the developed NPs for the ability to be 
produced by different methods and for resistance to simulated intestinal fluid 
and cryopreservation (Chapter IV). 
 
 This thesis research aimed to translate the scientific knowledge of CD44v6, 
nanomedicine and targeted drug delivery into a novel polymeric nanosystem that is 
capable of specifically recognizing human gastro-intestinal tract cancer cells that express 
CD44v6 while minimizing interactions with normal host tissues. This nanosystem is 
expected to be fully compatible in humans and to deliver a drug and/or diagnostic for in 
vivo therapeutic and/or diagnostic intervention. Lastly, this nanosystem is expected to 
display technological qualities that are amenable to pharmaceutic formulation beyond 
systemic administration (e.g. oral delivery or cryopreservation).  
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Discovery of anti-CD44v6 RNA aptamers by SELEX 
 
 
 
 This work was partly performed in the lab of Dr. Paolo Serafini at the Miller School 
of Medicine, University of Miami (USA) that has expertise in identifying and characterizing 
novel, cancer-related RNA aptamers [158] and their use with targeted nanoparticles [159]. 
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1. Abstract 
 Variant isoforms of CD44 containing exon v6 (CD44v6) have been implicated in 
metastasis and other cancer-related processes. Thus, this cell surface receptor is a 
potential therapeutic and/or diagnostic target in the treatment of various cancers. Akin to 
antibodies, aptamers are nucleic acid-based oligonucleotides that can adopt specific 
three-dimensional conformations with high specificity and affinity to a wide array of 
targets. With the intention of functionalizing nanoparticles, a novel RNA aptamer against 
human CD44v6, presented as a peptide or on the cell surface, was attempted to be 
identified through selected evolution of ligands by exponential enrichment (SELEX). 
Twelve rounds of peptide-based and seven rounds of cell-based SELEX were performed, 
and each output was quality controlled by spectrophotometry and gel electrophoresis. 
Various rounds of the peptide-based SELEX outputs were fluorescently-labelled and 
tested for binding to the CD44v6-derived peptide and to CD44v6-expressing cells. No 
CD44v6-specific enrichment was detected by either of the binding assays. Alternative 
methods, such as high-throughput sequencing and bioinformatics technologies, may be 
able to reveal sequence enrichment, but for now, a novel aptamer against human CD44v6 
was unsuccessfully identified. 
 
2. Introduction 
 CD44 is a highly alternatively-spliced, transmembrane surface receptor. Variant 
isoforms containing exon v6 (CD44v6) are associated with many aspects of cancer (e.g. 
metastasis [4], cancer stem cells [21] and hyperplastic lesions [19]) and are found in 
several tumor types (e.g. gastric, colorectal and head-and-neck cancers) [1, 32]. The 
overall aim of the thesis research is to develop nanoparticles (NPs) encapsulating a drug 
and/or diagnostic agent that specifically target CD44v6-expressing human gastric and/or 
colorectal cancer cells/tissues. Specific targeting can be achieved by tethering a ligand to 
the surface of the NP that has high specificity and affinity to human CD44v6. 
 Targeting ligands are typically based on antibodies, proteins/peptides, small 
molecules, or nucleic acids. Antibodies are commonly used ligands and offer many 
advantages such as the aforementioned specificity and affinity as well as availability [160]. 
Though, antibodies do have a few drawbacks such as potential immunogenicity and high 
discovery and production expense, among others. 
 Nucleic acid-based aptamers (single-stranded DNA or RNA) are an alternative and 
emerging class of molecules that can act as therapeutics alone [131] or as targeting 
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ligands [132, 133]. Aptamers are functionally similar to antibodies but present some added 
advantages such as smaller size, easier production and modification, desirable storage 
properties, nominal immunogenicity, and the ability to conjugate to 
biomolecules/nanoparticles [131]. 
 Novel aptamers are identified through the process called selected evolution of 
ligands by exponential enrichment (SELEX) (see section 3.2 of Chapter I) [135, 136]. 
SELEX is very malleable and can, and needs to, be adjusted according to the 
oligonucleotide composition (i.e. DNA or RNA) and/or the target molecule type (e.g. 
peptide or cell) [137]. For example, when identifying RNA-based aptamers, two extra 
steps of converting the RNA to DNA for PCR amplification and back to RNA are 
necessary as PCR is limited to DNA only (Figure 1). 
 
Figure 1. Schematic depicting the SELEX process of anti-CD44v6 RNA aptamer 
identification that was used herein. Briefly, the Sullenger library was first transcribed into 
RNA aptamers. The RNA aptamers were then incubated in the presence of the negative 
selection agent followed by unbound aptamers incubation with the CD44v6-specific 
selection agent (CD44v6 peptide or expressing cells). Unbound aptamers were washed 
away, and bound aptamers were either eluted from the magnetic beads or by antibody 
competition/displacement for the peptide or cell SELEX, respectively. Purified RNA was 
reverse transcribed into ssDNA and then converted into dsDNA by (emulsion) PCR. 
Throughout, the quality of the RNA/DNA was confirmed by agarose gel electrophoresis. 
This process represents one cycle of the SELEX protocol, and 12 peptide-based SELEX 
cycles were completed. More details about the peptide and cell SELEX protocols can be 
found in the document text. 
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 PCR is used to convert ssDNA to dsDNA. Unfortunately, many sequences are 
prone to unequal amplification (aka PCR bias) due to intrinsic differences in the 
amplification efficiency of templates during multi-template PCR [161]. One way to reduce 
PCR bias is to emulsify the reaction mixture to compartmentalize the PCR reactions within 
nano/picoliter water-in-oil emulsion droplets [162, 163]. In essence, a compartmentalized 
template with higher amplification frequency will exhaust its replication machinery 
components (e.g. primers and polymerase) and allow templates in other droplets to utilize 
their own compartmentalized components. 
 As no aptamers targeting CD44v6 were published in any academic journals or 
international patents and due to the licensing restrictions of AbD15179 use in vivo, SELEX 
was explored to identify a novel aptamer with specificity and affinity to human CD44v6. It 
was decided to try two different SELEX approaches based on peptide or cell surface 
presentation of human CD44v6 (Figure 1) intending to increase the rate of success. 
Emulsion PCR was utilized during the amplification stage to reduce amplification bias. 
Various rounds of the peptide-based SELEX outputs were then tested, unsuccessfully, for 
binding to a CD44v6-derived peptide or CD44v6-expressing cells. 
 
3. Materials and methods 
3.1. Materials 
 The cell culture media, penicillin/streptomycin (p/s), geneticin, trypsin/EDTA (T/E), 
versene, superscript III, Dynabeads MyOne Streptavidin T1, Taq polymerase and 
associated reagents, PCR primers, anti-CD44v6 monoclonal antibody (MA54), Alexa 
Fluor®647 C2 Maleimide and TMB substrate, were purchased from ThermoFisher 
Scientific. The fetal bovine serum (FBS) was from Biochrom. The biotinylated rat anti-
mouse Ly-6G was purchased from eBioscience, and the biotinylated SDS MW Standard 
mix was from Sigma. The DuraScribe® T7 Transcription Kit was purchased from 
Epicentre. The 5 mL cryovials and mini-stir bars were purchased from VWR. The horse 
radish peroxidase (HRP)-conjugated goat anti-human secondary antibody (anti-human-
HRP) and the BIO SPIN P6 (TRIS) size exclusion chromatography columns was from Bio-
Rad. Most chemicals were from Fisher Chemical or Sigma-Aldrich. 
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3.2. Cell culture 
 The MKN74 cell line was derived from a moderately differentiated tubular 
adenocarcinoma (intestinal-type carcinoma), and the cells were maintained in RPMI 
supplemented with 10% (v/v) FBS and 0.5 mg/mL geneticin (to maintain selection 
pressure; see below) and passaged twice per week diluted 1:10-1:20. The cells were sub-
cultured when ~80% confluency was reached, and they were maintained at 37 °C and 5% 
CO2 in a water-saturated atmosphere. CD44v6 expression was occasionally confirmed by 
FACS with anti-CD44v6 monoclonal antibody (MA54; Life Technologies) staining (data not 
shown). Mycoplasma detection by PCR was occasionally performed to ensure no 
contamination, and once during the studies, a short tandem repeat (STR) profile analysis 
ensured cell line purity. When relevant, the cells were detached with non-enzymatic 
Versene to maintain the integrity of the surface-bound receptors; however, trypsin/EDTA 
was used during sub-culture. 
 
3.3. Generation of transfected MKN74 cell lines 
 The human stomach adenocarcinoma epithelial cell line MKN74 was purchased 
from the JCRB Cell Bank (Japanese Collection of Research Bioresources Cell Bank). The 
parental cell line and isogenic variants were kindly provided by C. Oliveira, a co-
supervisor of the author. CD44v3-v10 (variant CD44-04 - ENST00000415148) cloned in a 
pCMV6-XL5 and pCMV6-AC backbone respectively, were purchased from OriGene. 
These variants were subcloned into a pIRES-EGFP2 expression vector. These vectors 
and the empty version (Mock) were transfected into MKN74 parental cells using 
Lipofectamine 3000 (Life Technologies) according to manufacturer’s instructions. After 
transfection, Mock and CD44v6 expressing cells were selected with geneticin and then 
sorted by magnetic bead capture using specific anti-CD44v6 (MA54) monoclonal 
antibody. Transfection and selection efficiency was assessed by immunocytochemistry 
and flow cytometry (C. Oliveira, unpublished data). For brevity, the MKN74-GFP cells 
overexpressing CD44v3-v10 are termed “MKN74-v6” and the parental MKN74-GFP cells 
are termed “MKN74”. It should be noted that the GFP expression of the cells dictated the 
choice of fluorophore used in cell-based studies. 
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3.4. RNA aptamer (library) and production details 
 The library was commercially synthesized to contain 40 DNA-based nucleotides 
(nts) that are degenerate (i.e. containing A, T, C or G) at each position to make up the 
tremendous diversity of the library. The 40 nts are then flanked at the 5’ and 3’ ends with 
~25 non-degenerate nts that serve as primer binding sites to initiate dsDNA synthesis 
during PCR. Based on the amount of DNA (1 µg) initially used during the DNARNA 
conversion, this equates to ~1012 unique aptamer sequences. DNA was converted to RNA 
with the DuraScribe® T7 Transcription Kit according to manufacturer’s instructions. It is 
important to note that the reagents must be added in the order specified in the kit. 
Importantly, the RNA in this kit is resistant to RNase A degradation, because the 
canonical CTP and UTP are replaced with 2′-Fluorine-dCTP (2′-F-dCTP) and 2′-Fluorine-
dUTP (2′-F-dUTP). 
 Lastly, the RNA that was from the initial library production or eluted from the beads 
(see section 3.7) or from the supernatant of mAb-competed CD44v6-expressing cells (see 
section 3.8) was first column purified (Qiagen RNeasy kit) according to manufacturer’s 
instructions. The RNA was then reverse transcribed to single-stranded DNA (ssDNA) with 
the superscript III kit (ThermoFisher) according to manufacturer’s instructions. Here, the 
Sul3’ primer (Table 1) was used to form the dsDNA initiation point for the reverse 
transcriptase. The thermal cycler profile was 65°C for 5 min and then slowly cooled down 
to 4°C over a one hour period. The enzyme was then inactivated by bringing the 
temperature to 55°C for 1 hr and 70°C for 15 min. The resultant ssDNA product was used 
to feed the (emulsion) PCR for conversion to dsDNA (see section 3.5). 
 
Table 1. Sequences of the primers used during RNA to ssDNA conversion and (emulsion) 
PCR amplification to dsDNA. 
Primer Sequence (5’  3’) 
Sul3’ TCTCGGATCCTCAGCGAGTCGTC 
Sul5’ GGGGGAATTCTAATACGACTCACTATAGGGAGGACGATGCGG 
 
3.5. Emulsion PCR 
 The emulsion PCR (ePCR) was based on these two references [162, 163]. First, 
prepared 10 mL of oil mixture containing 9.5 mL mineral oil, 450 uL span 80, 50 uL 
Tween-80, 5 uL Triton-X-100, mixed thoroughly by gentle inversion, and used within the 
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day it was made. A typical 250 uL PCR reaction mixture contained 50 pM of the Sul3’ and 
Sul5’ primers, 10 pM dNTPs and 25 uM MgCl2. An important component of the PCR 
mixture is the inclusion of 1% bovine serum albumin (BSA) [162]. The Sul5’ primer 
incorporates T7 RNA polymerase binding site for conversion of dsDNA to RNA. The PCR 
reaction was emulsified in 2X volume of oil (e.g. 250 uL PCR reaction + 500 uL oil). 
Emulsion was performed in appropriate sized vessel (e.g. 5 mL Wheaton cryovial) 
containing a mini stir bar at ~1000 rpm. PCR reaction was added to oil 10 uL at a time and 
emulsified for a further 5 min. The emulsion was then aliquoted to PCR tubes at 50-100 
uL/tube and placed on a thermal cycler as normal. The thermal cycler profile was as 
follows: (94°C, 30 sec; 52°C, 20 sec; 72°C, 25 sec) 3 times  (94°C, 30 sec; 54°C, 20 
sec; 72°C, 25 sec) 20 times  72°C, 5 min  hold at 10°C. 
 
3.6. Output quality control 
 After the PCR occurred, all products were recombined into an Eppendorf tube and 
centrifuged at 13,000xg for 5 min to separate the oil from the PCR mixture, and the top oil 
layer was carefully removed. One mL of water-saturated diethyl ether was added to the 
PCR mixture and vortexed. The top ether layer was carefully removed, and the process 
was repeated with an additional 1 mL ether. The residual ether was evaporated in a fume 
hood for ~1 hr. The PCR mixture was column purified with QIAquick PCR Purification Kit 
(Qiagen) according to the manufacturer’s instructions. The quantity and quality of the 
dsDNA was determined by spectrophotometric analysis (NanoDrop 1000) and 2% 
agarose gel electrophoresis, respectively. 
 It is relevant to note that ePCR was replaced by normal PCR after round 8 of the 
peptide SELEX, because the advantage of ePCR was assumed to have been severely 
reduced after so many rounds. 
 
3.7. SELEX using a peptide derived from human CD44v6 
 Here, peptide SELEX was based on RNA aptamer binding to a peptide that is 
derived from human CD44v6. The same peptide sequence that was used to select and 
screen for an anti-CD44v6 Fab was chosen, as this biochemical tool has a proven track 
record of successful synthesis and functional anti-CD44v6 ligand discovery [164]. The 
peptide sequence (N- to C-terminus) = biotin-GNRWHEGYRQTKEDS. The peptide was 
biotinylated to allow for capture with the streptavidin-coated beads. One SELEX cycle 
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began by incubating 1 ug of the polyclonal aptamers with ~30 pmol of an irrelevant 
biotinylated protein (biotinylated rat anti-mouse Ly-6G = rounds 1-7; biotinylated SDS MW 
Standard mix = rounds 8-12) in 300 uL of peptide SELEX buffer (0.5 mM MgCl2 + 1 mM 
CaCl2 in 1X PBS; pH 7.4) followed by incubation at 65°C for 5 min and then to room 
temperature (RT) for 10 min on a rotator. The negatively-selected aptamers were then 
captured with 200 ug streptavidin-coated magnetic beads (Figure 1). The beads were 
then discarded. In principle, this negative selection should reduce the amount of aptamers 
that are specific to streptavidin, the magnetic beads, biotin and proteins in general. The 
biotinylated CD44v6 peptide was then added to the supernatant for 10 min and captured 
with the beads (Figure 2). The beads were washed with increasing stringency with each 
SELEX cycle. The aptamers were eluted from the magnetic beads using an RNA 
purification kit (Qiagen) with slight modifications to the manufacturer’s protocol. In total, 12 
rounds of peptide SELEX were performed. 
 
 
 
Figure 3. Schematic depicting the positive selection of the peptide SELEX protocol. After 
the aptamer pool was negatively selected (Figure 1), they were incubated with the 
biotinylated CD44v6 peptide and captured with streptavidin-coated magnetic beads. 
Increasingly stringent washes were performed to remove non-specific aptamers, and RNA 
bound to the beads was subsequently purified. 
 
3.8. SELEX using human cells expressing CD44v6 
 Cell SELEX [165] was also used as an alternative protocol as the cell-based tools 
were already available. The negative selection involved incubating the polyclonal 
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aptamers first with MKN74 cells that do not express CD44v6 to deplete aptamers that are 
specific to the parental cell but not to CD44v6. These cells were centrifuged and 
discarded. The supernatant containing the depleted aptamers was then incubated with 
cells that express the variant isoform of CD44 containing exons v3 through v10 (MKN74-
CD44v6+). To ensure that only exon v6-specific, and not any of the other exons (v3 
through v5 or v7 through v10), aptamers were enriched, the anti-CD44v6 monoclonal 
antibody (MA54) was used to compete off aptamers that were present on the same 
epitope of CD44v6 that the mAb recognized. As this mAb has ~1 nM EC50 binding (data 
not shown) to these cells, it was assumed that only aptamers with lower affinity than 1 nM 
would be displaced by the mAb in equilibrium conditions. The supernatant of mAb-treated 
MKN74-CD44v6 cells was then used for RNA purification. In total, 7 rounds of cell SELEX 
were performed. 
 
3.9. Fluorescent labeling of polyclonal RNA aptamers 
 In order to track the polyclonal RNA aptamers from selected rounds of enrichment, 
the 5' EndTag Labeling DNA/RNA Kit (Vector Labs) was used according to manufacturer’s 
instructions to fluorescently label the aptamers with Alexa647. Briefly, a thiol group was 
added to the 5’ end of the aptamers with the kit to allow for covalent conjugation to the 
maleimide group of the Alexa647. Removal of non-conjugated Alexa647 was 
accomplished by size exclusion chromatography using the BIO SPIN P6 columns 
according to manufacturer’s instructions. The positive conjugation was only inferred since 
the resultant RNA aptamer product contained a blue color and could be measured by 
spectrophotometry with the NanoDrop. 
 
3.10. Binding of fluorescent polyclonal RNA aptamers on v6 peptide or cells 
 To test for enrichment of CD44v6-specificity, fluorescent, polyclonal aptamers from 
rounds 4, 8, and 12 were subjected to a similar peptide or cell binding procedure as that 
found during the (+) selection step of the corresponding SELEX (Figure 1). Unfortunately, 
none of the cell SELEX RNA material was tested, and only one replicate was performed 
throughout due to limited RNA and labeling reagents. 
 During the peptide binding test, 50 pmoles of each round of aptamers from the 
peptide SELEX were incubated with either the biotinylated CD44v6-derived peptide or 
MW standard (negative control) for 1 hr in 300 uL peptide SELEX buffer (see section 3.6). 
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This was followed by capture with 20 ug of streptavidin-coated magnetic beads for 10 min 
and 5 rinses before measuring the red channel fluorescence intensity by FACS 
(FACSCanto II; BD Biosciences).  
 During the cell binding test, MKN74-CD44v6 or MKN74 (negative control) cells 
were first non-enzymatically detached from the culture flask, counted, treated with 0.1% 
sodium azide and 10% FBS and kept on ice. Then, 50 pmoles of each round of aptamers 
from the peptide SELEX were incubated with 50,000 of either cell line in PBS for 2 hrs. 
This was followed by two washes with PBS, and fluorescence intensity was measured by 
FACS.  
 
3.11. Quality control of peptide SELEX protocol with anti-CD44v6 Fab 
 Based on the peptide SELEX protocol (see section 3.6), 125 nM of the anti-
CD44v6 Fab, AbD15179, or a negative control Fab in 300 uL of the peptide SELEX buffer 
was incubated with 333 nM of the biotinylated v6 peptide for 30 min at RT. The complex 
was captured with streptavidin-coated magnetic beads for 20 min. The beads were then 
washed three times and incubated with goat anti-human-HRP at 1:1000 for 30 min with or 
without 20 min pre-incubation of the beads/peptide/Fab complex in 1% BSA for 20 min. A 
similar assay was performed, but the peptide was first captured by the beads before 
incubation with the Fab. In all versions, the beads complex was incubated in 50 uL of TMB 
for ~15 min, and the reaction was stopped with 50 uL of 2 M sulfuric acid. The absorbance 
was measured at 450 nm with a microplate reader. 
 
4. Results and discussion 
 In order to identify novel RNA aptamers to human CD44v6, both peptide and cell 
SELEX was employed in parallel. A total of twelve rounds of peptide SELEX and seven 
rounds of cell SELEX were performed. The peptide SELEX strategy was designed to 
maintain the peptide-aptamer binding in solution conditions as this is usually more optimal 
during ligand discovery. More rounds of peptide SELEX were performed due to the 
directed expectation of better success since using this peptide as a selection antigen was 
essential in identifying an anti-CD44v6 Fab fragment [164]. Emulsion PCR was employed 
to reduce amplification bias during the dsDNA amplification step [162, 163], and quality 
controls of the resulting products were performed by gel electrophoresis. If successful, 
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these aptamers would ultimately be used as ligands to target NPs to CD44v6-expressing 
cells. 
 
4.1. Quality control of SELEX outputs 
 Each round of SELEX generated electrophoresis gels at the conversion of 
amplified dsDNA to RNA aptamers and from the ssDNA, after RNA aptamer enrichment 
and ssDNA conversion, to dsDNA. These steps were important to control the quality of the 
resultant products to ensure they were at the correct size. Figure 3 shows representative 
examples of gels demonstrating the expected sizes (~100 bp) of the dsDNA (Figure 3a) 
and the RNA aptamers (Figure 3b) and no unexpected amplified products. These quality 
controls (QCs) were performed for every dsDNA and RNA aptamer product for each 
round of peptide or cell SELEX. During the times where they did not pass QC or quantities 
were not sufficient, the reaction was repeated, with modifications if necessary, until the 
expected size or quantity was achieved. 
 
 
Figure 3. Representative quality control of dsDNA (a) and RNA aptamers (b) by agarose 
gel electrophoresis. Round 8 from the peptide SELEX is shown to demonstrate that the 
dsDNA and RNA aptamers (RNA) are migrating at ~100 base pairs (bp), which is at the 
expected size of 105 bp. Also, only some primer dimer (*) formation for the no template 
control (NTC) not seen in the dsDNA. Lad = ladder. 
  
4.2. Enrichment of anti-CD44v6 RNA aptamers 
 Upon completion of the SELEX cycles, enrichment of CD44v6 specificity was 
attempted by testing for binding of fluorescently-labelled polyclonal aptamers to v6-
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expressing cells or the v6 peptide. Positive enrichment would be expected if there was an 
increase in binding as the round number increased. Since more rounds of peptide SELEX 
were performed, the focus was on a sampling of those outputs (i.e. rounds 4, 8 and 12).  
 During the cell binding assay, a very similar protocol to the positive selection step 
of the cell SELEX was followed except fluorescence intensity of the cell/aptamers complex 
was measured by FACS (Figure 4a). Only a very slight increase in fluorescence was 
observed on the aptamer-treated MKN74-CD44v6 cells compared to the unstained cells, 
and the signal did not increase with each higher round number. However, there was 
higher fluorescence for the MKN74 cells (negative control) than for the positive cells. This 
suggests that there was no CD44v6 enrichment. 
 
Figure 4. No enrichment of CD44v6-specificity of fluorescent, polyclonal RNA aptamers 
from rounds 4, 8 and 12 (R4, R8 and R12) of the peptide SELEX outputs on the (a) 
CD44v6-expressing MKN74 (MKN74-v6) cells or on the (b) CD44v6-derived peptide (v6 
peptide). (a) 50 pmoles of Alexa647-labeled aptamers were incubated with either MKN74-
v6 or MKN74 cells followed by 2X washes. Unstained cells (US) were used as a baseline 
of fluorescence. (b) 50 pmoles of Alexa647-labeled aptamers were incubated with either 
the biotinylated v6-peptide or the negative control, biotinylated MW standard mix (MW 
Std), and captured with streptavidin-coated, magnetic beads. Fluorescence in both assays 
was monitored by FACS. MFUs = mean fluorescence units. 
 
 During the peptide binding assay, a very similar protocol to the positive selection 
step of the peptide SELEX (Figure 2) was followed except fluorescence intensity of the 
magnetic bead/v6 peptide/aptamers complex was measured by FACS (Figure 4b). No 
fluorescence was observed in the v6 peptide captured aptamer binding test, suggesting 
that there was no enrichment. The only fluorescence that was measured was when the 
aptamers were in the presence of the negative control biotinylated MW standard mix. This 
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was not expected, but it could be explained that the polyclonal aptamer mix has more 
places to bind in the many different proteins found in this mixture. If this was true, then the 
decrease in fluorescence seen with the increase in round number was expected, because 
this mixture was used as a negative selector to deplete non-specific aptamers. However, 
this is just speculation.  
 
4.3. Test of peptide SELEX protocol with anti-CD44v6 Fab 
 After the SELEX procedures and the enrichment were not validated, a quality 
control test was performed to ensure the robustness of the positive selection step of the 
peptide SELEX protocol (Figure 2). This was accomplished by exploiting a known binder 
of the CD44v6-derived peptide, an anti-CD44v6 Fab, AbD15179 [40, 164] while using a 
slightly modified peptide SELEX protocol in an in solution-based ELISA format. To explore 
the possible issues with, and possible improvements of, the protocol, two variations were 
investigated: presence/absence of BSA blocking and Fab binding before or after 
streptavidin-coated magnetic bead capture of the biotinlyated v6 peptide. In order to 
replicate the initial peptide SELEX protocol, the Fab was tested in equivalent molar 
amounts as that of the aptamers. The QC assay here that was most similar to the peptide 
SELEX protocol was the Fab + peptide incubation before capture with the beads without 
BSA block (Figure 5a).  
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Figure 5. Quality control assay to validate the integrity of the peptide SELEX protocol. An 
anti-CD44v6 Fab ((+) Fab) vs. a negative control Fab ((-) Fab) was incubated with the 
biotinylated v6 peptide (pep) either before (a and b) or after (c and d) capture with 
streptavidin-coated magnetic beads. Fab presence was detected with anti-human-HRP 
and quantified by measuring absorbance of the TMB substrate. These assays were 
performed without (a and c) or with (b and d) BSA block before addition of the anti-human-
HRP. In all versions, a no Fab control (no Fab) was performed in parallel. Abs 450 nm = 
absorbance at 450 nm. error bars represent the standard error of n=3 replicates. 
 
 No specific binding of the Fab to the v6 peptide, compared to the negative 
controls, was detected in any of the conditions tested (Figure 5). Higher signals were 
observed in the samples without any Fab (no Fab) present and without BSA block 
(Figures 5a and 5c). This was probably because of increased non-specific binding of the 
anti-human-HRP to the beads since they were not previously exposed to any protein (i.e. 
Fab or BSA). The lack of v6 Fab + peptide specific binding using this protocol suggests 
that the protocol itself is flawed. Though, it must be noted that even though Fab amounts 
were similar to those of the aptamers in the SELEX protocol, the assay may have not 
been sensitive enough to detect the amount of Fab used. Because the Fab can bind to the 
peptide in a plastic well-based, ELISA format (see Chapter IV) is further evidence that the 
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peptide SELEX protocol is not a robust method for the discovery of anti-CD44v6 RNA 
aptamers. 
 
5. Conclusions 
 In the search for a novel RNA aptamer that targets human CD44v6, two different 
SELEX methods were attempted. Both strategies were designed to accomplish the same 
goal but from different approaches. The cell SELEX outputs were not tested for 
enrichment due to limited time and resources. The focus was placed on the peptide 
SELEX and the resulting outputs as this was considered the protocol with more likelihood 
for success based on the selection of the anti-human CD44v6 Fab, AbD15179 [164]. 
Unfortunately, enrichment of CD44v6 specificity was not observed based on the lack of 
binding to both CD44v6-expressing cells and to the peptide itself (Figure 4). The quality 
control assay where the positive selection step of the peptide SELEX protocol using 
AbD15179 (Figure 5) highly suggests that the protocol itself is flawed leading to the lack 
of CD44v6 enrichment. In hindsight, this QC assay should have been performed prior to 
the laborious and time-consuming 12 rounds of peptide SELEX. Then, the focus could 
have been on using a plate-based SELEX format which is known to work with AbD15179 
(see chapter IV). It is also important to note that just because enrichment for CD44v6 was 
not measured does not mean that it did not occur. Using high-throughput NGS and 
bioinformatics techniques may have proven to be a more sensitive method to identify 
enriched aptamers [138, 139].  
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CHAPTER IV 
 
 
Targeting of human CD44v6 with Fab-conjugated, 
fluorescent nanoparticles 
 
 
Parts of this chapter were based on the following publications: 
- Kennedy P.J., Sousa, F., Ferreira D., Nestor M., Oliveira C., Granja P.L. and Sarmento 
B. 2018. Targeting of Fab-conjugated PLGA nanoparticles to cancer cells expressing 
human CD44v6. Under review.  
-Kennedy P.J., Pereira I., Ferreira D., Nestor M., Oliveira C., Granja P.L. and Sarmento 
B. 2018. Impact of surfactants on the target recognition of Fab-conjugated PLGA 
nanoparticles. Eur J Pharm. Biopharm. 127:366-70. 
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1. Abstract 
 CD44 isoforms containing exon v6 (CD44v6) have been implicated in many cancer 
associated processes including metastasis and exosome-mediated pre-metastatic niche 
formation. It is a receptor for hyaluronic acid (HA) and a co-receptor for HGF and VEGF, 
together with c-Met and VEGFR-2, respectively. CD44v6 is also expressed in cancer stem 
cells and (pre-)malignant gastric lesions. Therefore, CD44v6 has potential as a target for 
early cancer diagnosis and/or for therapeutic intervention. Targeted drug delivery with 
antibody-decorated nanoparticles (NPs) offers a possible strategy for the treatment and/or 
diagnosis of metastatic carcinoma. Thus, NPs decorated with an engineered human Fab 
that specifically target human CD44v6 (v6) were developed and characterized. Initial 
studies using polystyrene latex microspheres (FluoSpheres®) had many problems with 
aggregation and demonstrated no specific binding to CD44v6-expressing cells. Though, 
secondary attempts at developing Fab-decorated, poly(lactic-co-glycolic acid) (PLGA)-
based NPs (v6 Fab-PLGA NPs) were successful. The v6 Fab-PLGA NPs displayed 
spherical morphology around 300 nm and negative charge. They strongly bound to a 
CD44v6-derived peptide and, more importantly, to cells that endogenously and 
exogenously express CD44v6, but not to non-expressing cells and cells expressing the 
standard form of CD44. v6 Fab-PLGA NPs produced in 2% polyvinyl alcohol were unable 
to bind to the cells, and NPs produced in 2% Pluronic F127 demonstrated the highest 
binding compared to those produced in sodium cholate or Tween-80. Empty NPs had 
nominal cytotoxicity at 50 µg/mL. Lastly, v6 Fab-PLGA NPs withstood simulated intestinal 
fluid exposure and cryopreservation. In conclusion, we envision NPs targeting CD44v6 as 
potential in vivo diagnostic agents and/or as anti-cancer agents in patients previously 
stratified with CD44v6+ carcinomas. 
 
2. Introduction 
 Overexpression of alternatively-spliced CD44 containing exon v6 (CD44v6) 
variants [1, 3] is frequent in carcinomas [5]. Clinical interest of CD44v6 began when 
studies showed that only metastasizing cell lines from two rat tumor types expressed 
CD44v6, and a metastatic phenotype from non-metastasizing cells could be gained by 
overexpressing CD44v6 [4]. These pioneering studies sparked a myriad of subsequent 
studies devoted to analyzing the role of CD44v6 in cancer biology and as a prognostic 
biomarker [7]. CD44v6 is a receptor for hyaluronic acid (HA) and is a co-receptor for HGF 
and VEGF in collaboration with the tyrosine kinases c-Met [10] and VEGFR-2 [12], 
respectively, both therapeutic targets of clinical relevance [13]. Presentation of the 
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cytokine HGF by CD44v6 to c-Met activates the Ras/ERK/AKT signaling pathway, thus 
stimulating cell migration and invasion [10, 15]. Furthermore, in some contexts, Ras 
signaling promotes CD44v6 splicing, which then leads to more Ras activation, thus 
resulting in a positive feedback loop stimulating cell cycle progression [16]. CD44v6 is 
also associated with exosome-mediated, pre-metastatic niche formation [18]. 
 In gastro-intestinal malignancies, CD44v6 is overexpressed in gastric cancer (GC) 
[19] and colorectal cancer (CRC), particularly in CRC stem cells (CR-CSCs) [21]. 
Paradoxically, it is overexpressed in pre-malignant gastric lesions as opposed to the 
normal gastric mucosa [19] and it is associated with chemo-resistance in a model of 
CD44v6-overexpressing CRC cells treated with common chemotherapeutic agents [166]. 
Recently, cultured circulating tumor cells (CTCs) derived from stage IV CRC patients were 
shown to express hallmarks of CR-CSC such as CD44v6 [27]. Gain of CD44v6 is 
associated with loss of E-cadherin [19, 167] helping to demonstrate its role in the 
epithelial-to-mesenchymal transition (EMT) [21], an integral process in metastasis [22]. 
Lastly, CD44v6 has been shown to be a marker of poor prognosis for GC [168, 169] and 
CRC patients [7, 167, 170]. Thus, CD44v6 holds tremendous promise as an in vivo target 
for therapeutic intervention [32] and/or (early) cancer diagnosis. 
  Targeted therapy regimens in the oncology clinic are increasingly based on tumor 
characteristics such as genetic mutations and/or cell surface markers. Antibodies, 
essential to the vertebrate immune system in pathogen identification and neutralization 
both outside and inside [77] the cell, dominate targeted therapy due to their exquisite 
specificity and affinity to countless targets. This is evidenced by the approval of >60 mAbs 
and >50 more in late-stage clinical trials [171]. Antibodies are quite malleable, often 
function as fragments, and recombinant antibody production and engineering is now 
commonplace [144]. More recently, antibodies are being exploited in targeted drug 
delivery [65] as bioconjugates with small molecule drugs (antibody-drug conjugates 
(ADCs)), peptides/proteins, other antibodies or nanoparticles (NPs) [172]. 
 Nanotechnology applied to medicine (nanomedicine) promises to greatly impact 
disease management through pharmacological enhancement mechanisms such as 
controlled release, a capacity to harbor a plethora of therapeutic/diagnostic payloads, 
intracellular delivery [173], multi-functionality [174], and responsiveness to environmental 
stimuli [175]. Importantly, NPs can be engineered to overcome biological barriers [44] 
such as the mucosa [55], and nanoencapsulation can overcome chemo-resistance [176]. 
As such, cancer is particularly receptive to nanomedicine [71], and several NPs are 
already routinely used in the clinic [45]. Classical nanosystems debatably [69] exploit the 
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enhanced permeation and retention (EPR) effect for “passive targeting” to tumors; 
however, “active targeting” exploits defined biochemical interactions (e.g. ligand-receptor) 
for recognizing specific tissues/cells and avoiding healthy tissue [65]. Thus, combining the 
aforementioned qualities of nanotechnology with antibodies [145, 177] is an extremely 
viable strategy for targeted drug delivery [172]. 
 Given the clinical relevance of CD44v6 in gastro-intestinal cancers, we set out to 
develop and characterize NPs with selectivity to human CD44v6 for downstream targeted 
drug and/or diagnostic delivery. As such, we utilized a well-characterized human Fab 
fragment specific to human CD44v6, AbD15179 [40, 164], and attempted to tether it to 
fluorescent NPs. Initial studies with polystyrene latex microspheres failed; however, 
subsequent studies with poly(lactic-co-glycolic acid) (PLGA) NPs were successful. These 
NPs were subsequently characterized for their physical parameters, binding to a CD44v6-
derived peptide and CD44v6 expressing cells and cytotoxicity. Additionally, the versatility 
of this nanosystem was explored by investigating their ability to be produced by different 
formulation methods, withstand simulated intestinal fluid (SIF) exposure and 
cryopreservation. 
 
3. Materials and methods 
3.1. Materials 
 The RPMI and DMEM cell culture media, penicilin/streptomycin (p/s), geneticin, 
trypsin/EDTA (T/E), versene, 200 nm green-yellow, amine-modified FluoSpheres®, sulfo-
SMCC linker containing 24 polyethylene (PEG) chains (SM(PEG)24), Alexa Fluor 555-
labelled, goat anti-human, TMB substrate, Alexa Fluor 546-labelled phalloidin were 
purchased from ThermoFisher Scientific. The fetal bovine serum (FBS) was from 
Biochrom. The core PLGA (50:50 LA:GA; 44,000 Da; 5004A) was kindly provided by 
Corbion. PLGA-FKR648 (20,000-30,000 Da) and PLGA-PEG-Mal (30,000:5000 Da) were 
from Polyscitech/Akina. The Pluronic F127 (aka Kolliphor Poloxamer 407) was from 
BASF. The commercially-synthesized CD44v6-derived peptide (biotin-
GNRWHEGYRQTKEDS-CONH2) was a kind gift from Dr. Paolo Serafini. The horse radish 
peroxidase (HRP)-conjugated goat anti-human secondary antibody (anti-human-HRP) 
was from Bio-Rad. The Amicon centrifuge filters (100 kDa MWCO) was from EMD 
Millipore. The Mowiol 4-88 mounting media, polyvinylalcohol (PVA), sodium cholate (Na 
Chol) and Tween-80 was from Sigma. Pancreatin was from Biozym. Most chemicals were 
from Fisher Chemical or Sigma-Aldrich. 
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3.2. Cell culture 
 The MKN74 cell line was derived from a moderately differentiated tubular 
adenocarcinoma (intestinal-type carcinoma), and the cells were maintained in RPMI 
supplemented with 10% (v/v) FBS and 0.5 mg/mL geneticin (to maintain selection 
pressure; see below) and passaged twice per week diluted 1:10-1:20. The GP202 cell line 
was derived from primary diffuse gastric carcinoma [178], and the cells were maintained in 
RPMI supplemented with 10% FBS (v/v) and 1% (v/v) p/s twice per week diluted 1:4-1:7. 
The cells were sub-cultured when ~80% confluency was reached, and they were 
maintained at 37 °C and 5% CO2 in a water-saturated atmosphere. CD44v6 expression 
was occasionally confirmed by FACS with anti-CD44v6 monoclonal antibody (MA54; Life 
Technologies) staining (data not shown). Mycoplasma detection by PCR was occasionally 
performed to ensure no contamination, and once during the studies, a short tandem 
repeat (STR) profile analysis ensured cell line purity. When relevant, the cells were 
detached with non-enzymatic Versene to maintain the integrity of the surface-bound 
receptors; however, T/E was used during sub-culture.  
 
3.3. Generation of transfected MKN74 cell lines 
 The human stomach adenocarcinoma epithelial cell line MKN74 was purchased 
from the JCRB Cell Bank (Japanese Collection of Research Bioresources Cell Bank). The 
parental cell line and isogenic variants were kindly provided by C. Oliveira, a co-
supervisor of the author. CD44v3-v10 (variant CD44-04 - ENST00000415148) and 
CD44std (variant CD44-03 - ENST00000263398) cloned in a pCMV6-XL5 and pCMV6-AC 
backbone respectively, were purchased from OriGene. These variants were subcloned 
into a pIRES-EGFP2 expression vector. These vectors and the empty version (Mock) 
were transfected into MKN74 parental cells using Lipofectamine 3000 (Life Technologies) 
according to manufacturer’s instructions. After transfection, Mock, CD44std and CD44v6 
expressing cells were selected with geneticin and then sorted by magnetic bead capture 
using specific anti-CD44v6 (MA54) and anti-CD44std (Cell Signaling) monoclonal 
antibodies. Transfection and selection efficiency was assessed by immunocytochemistry 
and flow cytometry (C. Oliveira, unpublished data). For brevity, the MKN74-GFP cells 
overexpressing CD44v3-v10 are termed “MKN74-CD44v6+”, the MKN74-GFP cells 
expressing the standard form of CD44 are termed “MKN74-CD44std” and the parental 
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MKN74-GFP cells are termed “MKN74”. It should be noted that the GFP expression of the 
cells dictated the choice of fluorophore used in cell-based studies. 
 
3.4. EC50 binding of re-engineered Fabs to peptide and cells 
 The human anti-human CD44v6 Fab, AbD15179 [40, 164], was commercially re-
engineered (Bio-Rad) to express three cysteine residues near the C-terminus of the Fab 
to allow for coupling to the maleimide functional groups of the NPs (see below). 
Henceforth, the re-engineered AbD15179 is termed “v6 Fab”. An irrelevant Fab without 
specificity to CD44v6 that was identified during the initial monoclonal screening stage and 
served as a negative control Fab was also re-engineered as above; henceforth, termed “(-
) Fab”. 
 Enzyme-linked immunosorbent assay (ELISA) was performed to determine the 
binding of the Fabs to a peptide derived from CD44v6. This was the same peptide antigen 
used in the initial selection and screen [164]. Briefly, 50 µL of 10 µM peptide (~1 µg) 
diluted in 50 mM bicarbonate/carbonate coating buffer at pH 9.6 (CCB) was added to 
each well of a 96-well black plate with moderate protein binding capacity for 3 hr. Blocking 
was achieved with 100 µL of 1% BSA in 1X PBS at pH 7.4 (PBS) for 1 hr. 50 µL of each 
Fab was serially diluted from 500 nM to 0.02 nM in PBS and incubated with the 
immobilized and blocked peptide for 3 hr. The Fabs were detected with 50 µL of anti-
human-HRP diluted 1:2500 in PBS for 1 hr. 50 µL of TMB substrate was added to the 
wells, and the reaction was stopped with 50 µL of 2M sulfuric acid. Absorbance at 450 nm 
was measured with a microplate reader (Synergy Mx; BioTek). Between each of the 
steps, each well was washed three times with 100 µL of PBS containing 0.1% Tween-20 
(PBST). All incubations took place at 37 °C and the reactions were performed in duplicate. 
 Fluorescence-activated cell sorting (FACS) was performed to determine binding of 
the Fabs to MKN74 cells with or without overexpression of human CD44v3-v10. Briefly, 
cultured cells were detached with versene and fixed with PBS supplemented with 10% 
FBS and 0.1% sodium azide (NaN3) (FACS buffer) for 1 hr. 10
5 cells were added to a 96-
well plate with round-bottom wells (Corning). Pelleted cells were resuspended in 50 µL of 
each Fab serially diluted from 500 nM to 0.02 nM in FACS buffer for 2 hr. The Fabs were 
detected with 50 µL of anti-human-Alexa Fluor 555 diluted 1:250 in FACS buffer for 1 hr. 
Three washes by centrifugation (300xg; 3 mins) of 100 µL of cold FACS buffer occurred 
between each of the steps, all incubations took place on ice and the reactions were 
performed with biological duplicates. Fluorescence intensity was measured with the 
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FACSCanto II flow cytometer (BD Biosciences) using the same voltage settings for all cell 
lines and between all experiments. The data was analyzed with FlowJo v10 by gating out 
cellular debris and doublets and determining the geometric mean (mean fluorescence 
units (MFUs) of the APC signal. Error bars represent the standard deviation of two 
replicates for both ELISA and FACS. 
 
3.5. Generation of Fab-decorated FluoSpheres® 
 200 nm green-yellow, amine-modified FluoSpheres® were first treated in a water 
sonication bath for 30 min prior to downstream preparation. Calculations were based on 
the number of amine groups per bead (2.4 x 106/bead) and the number beads and 
molecules of SM(PEG)24 linker and Fab in a given concentration of all. No linker and 106 
SM(PEG)24 linkers/bead were resuspended in PBS containing the experimental amount 
of FluoSpheres® for one hr. To remove non-associated SM(PEG)24 from the 
FluoSpheres®, three washes with PBS were performed by centrifugation at 5000xg and 
removal of supernatant from FluoSphere® pellet. The v6 or (-) Fab was added to the 
above FluoSpheres® at 10 or 1000 Fab molecules/bead in PBS for 1 hr at RT. To remove 
non-associated Fab from the FluoSpheres®, three washes with PBS were performed by 
centrifugation at 5000xg and removal of supernatant from FluoSphere® pellet. The 
FluoSpheres® were resuspended in PBS and stored at 4°C until further use. 
 
3.6. Generation of PLGA nanoparticles by nanoprecipitation 
 The base PLGA NPs were generated by nanoprecipitation (modified from [179]) 
with the following percentages: 80% core PLGA, 10% PLGA-FKR648 and 10% PLGA-
PEG-Mal. FKR648, a red channel fluorophore with absorbance at 642 nm and emission at 
663 nm, was implemented here so that the GFP from the cells would not interfere with 
detection of the NP fluorescence. Briefly, 20 mg of total PLGA polymer dissolved in 1 mL 
acetone were slowly injected (~3-4 mL/min) through a 25g needle into 20 mL 0.5% F127 
in ultrapure water while stirring at 300 rpm. The precipitated PLGA was kept stirring for 3-
4 hr, and then, the NPs were washed three times with 10 mL ultrapure water using 
Amicon centrifuge filters (100 kDa MWCO) at 3000xg. The final concentrations before 
conjugation (see below) equated to ~2 µg/µL of total PLGA and 2.5 µM maleimide. PLGA 
was stored under argon at -20 °C after usage. During the PTX encapsulation study, 4 mg 
of Paclitaxel (PTX) was also dissolved in the acetone along with the PLGA components. 
Downstream assays accounted for the additional mass imparted by the drug. 
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 During the impact of the surfactant on targeting studies, the PLGA NPs were 
prepared similarly as above. The surfactants were prepared in ultrapure water, and the 
percentages of PVA, Na Chol and F127 were based on weight:volume while Tween-80 
was based on volume:volume. In the initial study, the PLGA NPs were washed three times 
by centrifugation at 10,000xg for 20 min followed by resuspension in 10 mL ultrapure 
water. In the follow-up study with different concentrations of F127 and Tween-80, the NPs 
were washed three times with water using Amicon centrifuge filters (100 kDa MWCO) at 
3000xg. 
 
3.7. Generation of PLGA nanoparticles by water-oil-water (w/o/w) double emulsion 
 PLGA NPs were generated by a modified water-in-oil-in-water (w/o/w) double 
emulsion technique [180, 181] with the same percentages as for NPs produced by 
nanoprecipitation. 20 mg of total PLGA were dissolved in 1 mL of dichloromethane (DCM). 
Then, 80 μL of ultrapure water were added, and the polymeric solution was homogenized 
for 30 s using a Vibra-Cell™ ultrasonic processor with 70% of amplitude. After this 
homogenization, 4 mL of 0.5% F127 in water were added into the primary emulsion (w/o) 
and mixed with similar sonication conditions. Finally, the second emulsion (w/o/w) was 
added into 7.5 mL of the same surfactant solution. The solvent evaporation and washes of 
the resultant PLGA NPs were treated similarly as above. 
 
3.8. Fab conjugation to the PLGA nanoparticles 
 Stock Fabs were diluted to reach a final concentration of 1 µM in 1X PBS pH 7.4. 
The reducing agent tris(2-carboxyethyl)phosphine (TCEP) was added to the Fabs at a 
final concentration of 3 µM to allow for mild reduction of the C-terminal cysteines and 
incubated for 1-2 hours at 4 °C before addition to the NPs. Depending on the experiment, 
the necessary amount of PLGA was pelleted by centrifugation at 10,000xg for 10 min, and 
the pellet was resuspended in the 1 µM Fab solution to maintain a PLGA concentration of 
~25 µM (1 µg/µL). Initial studies used different molar ratios of Fab to PLGA during 
conjugation to the base NPs, but the results of this test dictated the use of a molar ratio of 
1:25 Fab:PLGA (which equals 1 µg of Fab per 20 µg of PLGA) for all subsequent studies, 
including the different surfactant study. NPs without Fab conjugation were processed 
similarly but with buffer only. After overnight incubation at 4 °C, the NPs were washed 
three times by centrifugation at 10,000xg at 4 °C with 200 µL of ultrapure water. The NPs 
were then resuspended in water/buffer/media as needed for the subsequent assays. All 
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NPs were maintained in low light conditions, and each formulation was performed in 
triplicate. PLGA-FKR648-PEG-Mal NPs were conjugated with the re-engineered, human 
anti-human CD44v6 Fab are termed “v6 Fab-PLGA NPs“, and those conjugated with the 
human negative control Fab are termed “(-) Fab-PLGA NPs”. NPs without any Fab 
conjugation are termed “bare PLGA NPs”. 
 
3.9. Physicochemical characterization of nanoparticles 
 Size and polydispersity (PdI) were determined by dynamic light scattering (DLS), 
and charge was determined by laser Doppler anemometry (LDA). Both DLS and LDA 
were performed with a Zetasizer Nano ZS (Malvern) incorporating the Smoluchowski 
model, and three measurements were taken for each of the triplicate NP formulations. 
Around 5 µg of NPs were diluted in 750 µL of 10 mM NaCl pH 7 for each sample yielding 
count rates around 200 kcps. Data is presented as the average of the triplicate NP 
formulations including the standard deviation. The association efficiency of PTX within the 
PLGA NPs was determined by HPLC of the supernatants according to protocol 
standardized in the Nanomedicines lab [182]. 
 Transmission electron microscopy (TEM) was used to visualize the morphology of 
the bare and v6 Fab-PLGA NPs. About 0.5 µg of NPs in water were dried onto 200 mesh 
Formvar Ni-grids without a counterstain. The NPs were observed and imaged at 25,000X 
and 120,000X magnifications at 80 kV with a JEM 1400 TEM (JEOL). Images were 
digitally recorded using an 1100W CCD digital camera (Orious). 
 
3.10. Determination of PTX association efficiency  
 During the toxicity studies (see section 3.15), the supernatant, after the 3 hr 
acetone evaporation and first centrifugation steps, was retained to monitor the efficiency 
of the encapsulation of PTX within the PLGA NPs. High pressure liquid chromatography 
(HPLC) was used to quantify the amount of PTX in the supernatant. A standard curve of 
known PTX concentrations was also run in parallel. The amount of PTX measured in the 
supernatant thus indirectly reflected the amount of associated PTX within the PLGA NPs.  
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3.11. Determination of Fab association efficiency to the PLGA NPs 
 ELISA was used to monitor the amount of Fab present on the PLGA NPs during 
the surfactant studies. The overall protocol is similar to that found in the EC50 binding of 
the Fabs only to the CD44v6-derived peptide (see section 3.4). Briefly, 10 µg of Fab-
decorated NPs in 50 µL CCB were adsorbed to the 96-well plate well in duplicate, blocked 
with 1% BSA and detected with anti-human-HRP at 1:5000 with 3X washes of PBST 
between each step. 
 
3.12. Binding of PLGA NPs to the CD44v6-derived peptide 
 ELISA was used to measure the binding of 10 µg of the v6 Fab-PLGA NPs to the 
CD44v6 peptide following a similar protocol as for the EC50 binding (see section 3.4). 
 
3.13. Binding of nanoparticles to the surface of cells expressing CD44v6 
 The protocol and downstream data manipulation was similar to that used during 
the EC50 binding of the free Fab (see section 3.4). Though, NP presence was determined 
by measuring the intensity of the red channel fluorophore FKR648; thus, forgoing the 
need for the anti-human secondary. Depending on the experiment, a defined quantity of 
NPs was incubated with 105 NaN3-fixed and FBS-blocked cells for ~2 hrs followed by 3X 
washes with 100 µL PBS. During Fab competition study, the cells were incubated with 50 
µL of 250 nM v6 or (-) Fab for 1 hr, without subsequent cell washing, prior to addition of 
the 10 µg v6 Fab-PLGA NPs. During protein corona study, the NPs were incubated with 
10% (v/v) FBS for 4 hr, without subsequent NP washing, prior to addition to the cells. 
Binding studies of w/o/w double emulsion, SIF-treated and freeze-dried NPs were 
performed with ~10 µg v6 Fab-PLGA NPs on MKN74-CD44v6+ and MKN74 cells as 
above (see section 3.4). 
 
3.14. Binding of nanoparticles to live cells 
 MKN74-CD44v6+ and MKN74 were seeded at 20,000 cells/well in 24-well plates 
and cultured for 3 days, giving ~70% confluency, prior to addition of the NPs. 10 µg of 
NPs was added to each well of cells in RPMI without the FBS and P/S supplements for 6 
hr. The cells were carefully washed 3X with 250 µL PBS.  
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 For the microscopy assay, the cells, plated on glass cover slips, were fixed in 4% 
paraformaldehyde for 20 min at RT and rinsed 3X with PBS. The cells were then 
permeabilized with 0.2% Triton-X100 for 7 min at RT and rinsed 3X with PBS. The cells 
were blocked in 10% FBS in PBS containing 0.1% Tween-20 (PBST) for 30 min at RT. 
The solution was then replaced with 300 µL PBST + 5% FBS containing 0.3 units of Alexa 
Fluor 546 labelled-phalloidin and incubated for 4 hrs at RT. The cells were rinsed 3X in 
PBS and mounted on glass microscope slides with mounting media and dried overnight at 
RT in the dark. The stained and fixed cells were observed and imaged with an SP5 
confocal microscope (Leica) using the appropriate laser and filter combinations. Image 
analysis was performed with the LAS AF Lite software (Leica). The 20X magnification 
images are shown as maximum projections of 13-15 Z-stacks with a distance of 2 µm 
between them. The 63X magnification image of the MKN74-CD44v6+ cells incubated with 
v6 Fab-PLGA NPs was taken with 16 Z-stacks with 0.29 µm distance between them. One 
image is shown as a maximal projection of the Z-stack, and the other is shown as an 
interior Z-stack with the Z-dimension displayed to the right and below.  
 For the FACS assay, the cells were detached with T/E, pelleted by centrifugation 
and washed once more with PBS before FACS measurement. 
 
3.15. Cytotoxicity of PLGA NPs 
 MKN74-GFP/CD44v6+ and GP202 cells were seeded at 4,000 and 10,000 
cells/well in 96-well plates, respectively, and cultured for 2 days, giving ~50% confluency, 
prior to the addition of the NPs. The culture media for all cell lines was replaced with 80 µL 
of fresh media (containing 10% FBS) followed by the addition of 20 µL of media containing 
5 µg of freshly-prepared NPs were added to each well of cells in media. Duplicates of 
each of the formulation triplicates were tested. Three plates were loaded equally reflecting 
the three time points. Two were incubated for 6 hrs and replaced with 200 µL fresh media 
after being rinsed 2X with 100 µL PBS, one plate for 24 hrs and another for 48 hrs total. 
The third plate was cultured with the NPs for 24 hrs and then rinsed 3X with 100 µL PBS. 
At the end of each time point, the media or PBS was replaced with 100 µL of media 
containing 0.5 mg/mL of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) solution and incubated for 4 h. Two assay replicates were performed for each of 
the three formulation replicates. Free PTX was dissolved in DMSO before addition to the 
media at 10, 1 and 0.1 µg/mL. The PTX levels of free PTX at 10 and 1 µg/mL correspond 
to similar levels of PTX at 50 and 5 µg/mL for the NPs based on production design. In all 
plates, six wells each were devoted to 1% Triton-X-treated cells (“background”) or media 
CHAPTER IV 
58 
 
only (“untreated”). All culture conditions were maintained as above. The reaction was 
terminated by replacement of the MTT solution with 100 µL dimethyl sulfoxide. After 15-20 
mins, reduced MTT levels were measured with a microtiter plate reader (Biotek Synergy 
Mx) at 590 nm and 630 nm absorbance (abs). During the calculations, the 630 nm abs 
was subtracted from the 590 abs, and the % of MTT reduction was calculated from this 
subtracted value (Equation (1)). 
Equation (1)  MTT reduction (%) = 
Experimental value - background
untreated - background
 × 100 
 
3.16. Simulated intestinal fluid treatment of v6 Fab-PLGA NPs 
 The simulated intestinal fluid (SIF) was composed of 50 mM KH2PO4 and 15 mM 
NaOH and brought to a pH of 6.8. Pancreatin was added to the buffer at a concentration 
of 1% (w/v) and mixed for 1 hr. The mixture was then centrifuged at 10,000xg for 10 min. 
The supernatant was removed and used fresh. It should be noted that much of the 
pancreatin powder did not go into solution; therefore, the true concentration was unknown. 
10 µg of NPs (n=3 formulation replicates) were added to 200 µL of SIF with or without 
pancreatin for 15 or 60 min at 37 °C. The NPs were then centrifuged and washed 1X with 
200 µL PBS followed by resuspension in 50 µL PBS for an immediate cell binding assay 
(see above). Control NPs were treated with PBS pH 7.4 for 60 min. 
 
3.17. Cryopreservation of v6 Fab-PLGA NPs 
 A modified cryopreservation protocol based on [183] was used to assess the 
storage capabilities of the NPs. Freshly-prepared v6 Fab-PLGA NPs were resuspended in 
1 mL of 10% (w/v) trehalose in water. NPs resuspended in 1 mL of water were used as a 
negative control. All formulations were frozen at -80 °C in lobind tubes with perforated 
caps for 6h and then transferred to a FreeZone lyophilizer (LabConco) set to 0.008 mbar 
for 24h. NP replicates were either stored in the dark at RT, 4 °C, or -20 °C for two weeks 
(n=3 for each temperature). The NPs were then resuspended in 1 mL of water for ~1 hr 
and pelleted by centrifugation at 10,000xg for 15 min. The supernatant was removed, and 
the NP pellet was resuspended in PBS and maintained on ice for 1-2 hrs before cell 
binding studies. 
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3.18. Statistics 
 GraphPad Prism 6 analysis was used to analyze the significance levels (ANOVA 
with Dunnet’s test) and determine the EC50 value. The results represent the mean value 
with a standard deviation of three replicates. 
 
4. Results and discussion 
 The general objective of the overall study was to develop and characterize NPs 
that specifically target cells (over)expressing CD44v6 for the purpose of oncological drug 
and/or diagnostic delivery. Amine-modified, polystyrene latex microspheres at 200 nm 
with yellow/green fluorescence (FluoSpheres®) were initially tested as, in principle, they 
could allow for the directed conjugation of the re-engineered, anti-human CD44v6 Fab 
using a maleimide-based linker. Additionally, the initial idea was to produce and 
functionalize chitosan-based NPs, which harbor amine functional groups, and thus, the 
FluoSpheres® acted as a fluorescent surrogate for proof-of-principle studies. The decision 
to work with PLGA instead of chitosan was based on the current focus of the 
Nanomedicines group and the easier production and modification possibilities. For 
instance, amine- or maleimide-modified PLGA as well as PLGA-conjugated to a 
fluorophore could be incorporated.  
 
4.1. General nanoparticle design ensures PEGylation and optimal Fab orientation 
 Antibody recognition of its cognate antigen (e.g. CD44v6) occurs via the antigen-
binding, variable regions of the heavy and light chains (see section 3.1, Chapter III) [144]. 
The commonly-used conjugation methods based on EDC/NHS rely on the amine group of 
one binding partner to be coupled to the carboxyl group of the binding partner. When 
conjugating amine-modified NPs with an antibody, this means that all the available 
carboxyl groups of the antibody (i.e. C-terminus, aspartic acid and glutamic acid) are 
subject to conjugation to the NP. This results in a randomly-directed conjugation such that 
the antigen-binding domain of the antibody may or may not be available for antigen 
recognition, and, ultimately, may reduce binding specificity, affinity and/or avidity.  
 Conjugating the antibody such that the antigen-binding domain of every molecule 
is oriented for proper antigen recognition is ideal. Because AbD15179 is a recombinant 
protein, it was re-engineered to express three C-terminal cysteines to be able to exploit 
the thiol-Michael addition click reaction based on conjugation to a maleimide functional 
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group [184]. The thiol group from the cysteines reacts to the activated ester group of the 
maleimide to form a covalent bond. In this study, the initial plan was designed to use a 
sulfo-SMCC linker containing 24 polyethylene glycol chains (SM(PEG)24) to bridge the 
amine functional groups of the NPs to make a maleimide available for conjugation to the 
thiols of the C-terminal cysteines of the Fab (Figure 1). PLGA-based NPs were also 
attempted by just incorporating PLGA-PEG-maleimide to avoid the need for the linker (see 
below) 
 
 
Figure 1. Schematic depicting the conjugation of the re-engineered AbD15179 (anti-
CD44v6 Fab) to the nanoparticles (NPs). Briefly, the NHS ester of the SM(PEG)24 linker 
reacts with the amine group of the NPs, and the maleimide of the linker reacts with the 
thiols of the C-terminal cysteines of the Fab to form the covalent bridge between the two. 
This ensures that the NPs are PEGylated and all the conjugated Fabs have their antigen-
binding domain available for CD44v6 recognition. Adapted from ThermoFisher Scientific. 
 
4.2. Re-engineered AbD15179 maintains its binding affinity for human CD44v6 
 AbD15179 is a human Fab antibody fragment from the HuCAL® PLATINUM library 
[39] that was selected and screened for binding to human CD44v6 for radio-
immunodiagnostics of head-and-neck squamous cell carcinoma (HNSCC) [40, 164]. 
AbD15179 was previously shown to have KD values (affinity) ranging from ~6-70 nM on 
proteins derived from CD44v6 and ~2-10 nM on CD44v6-expressing cells as determined 
by surface plasmon resonance (SPR) and LigandTracer Grey, respectively [164]. 
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Importantly, radiolabelled AbD15179 also demonstrated moderate overall tumor-to-organ 
specificity in mouse xenograft models [40]. Due to its specificity to CD44v6, human origin 
and engineering malleability, AbD15179 was exploited as a targeting ligand for 
drug/diagnostic delivery mediated by PLGA NPs. 
 In order to ensure gastro-intestinal CD44v6-expressing cell specificity, we used a 
gastric cancer cell model system based on cells with forced overexpression of CD44v6, 
previously developed by the group. MKN74 cells are a good model for these studies as 
the parental cells are naturally devoid of any CD44 expression due to hypermethylation of 
the promoter [185], and therefore constitute the ideal cell line for overexpression studies. 
We then used MKN74 cells with forced CD44v6 expression (MKN74-CD44v6+) as the 
testing model, that were properly controlled with MKN74 cells expressing the empty vector 
(MKN74) or the standard version of CD44 (MKN74-CD44std), which is a ubiquitously 
expressed isoform. Furthermore, we used another cell line that endogenously express 
CD44v6 as well as other CD44 alternative splicing isoforms (GP202), to monitor specificity 
in a naturally occurring context. 
 Because ligand orientation impacts the targeting capability of ligand-decorated 
NPs [172], we had AbD15179 commercially re-engineered to express C-terminal 
cysteines to allow for ligand conjugation to the NPs via thiol-maleimide based chemistry 
(more below). We first aimed to ensure that the re-engineering of AbD15179 did not alter 
its affinity to the CD44v6-derived peptide and CD44v6-expressing cells. Additionally, we 
needed to ensure that the transfected MKN74 cell-based system could robustly monitor 
binding of the Fab and Fab-decorated NPs. To do so, we serially diluted the v6 Fab and 
monitored the binding response to the peptide and to our cell lines by ELISA and FACS, 
respectively. Importantly, we utilized a negative control Fab ((-) Fab) to ensure that any 
downstream NP binding is due to CD44v6 specificity and not from the mere presence of a 
conjugated protein. 
 The approximate half maximal effective concentration (EC50) of the v6 Fab to the 
peptide was ~90 nM, and the (-) Fab had nominal binding (Figure 2a). The EC50 of the v6 
Fab to the MKN74-CD44v6+ cells was ~25 nM and ~10 nM to GP202 (Figure 2b). As 
expected, there was nominal binding of the v6 Fab to the parental MKN74 cells at the 
highest concentration, and the (-) Fab at 500 nM had nominal binding to all three cell lines 
(Figure 2c). The higher overall fluorescence of the v6 Fab on MKN74-CD44v6+ 
compared to GP202 was expected. Because the original AbD15179 had KD values ~5-70 
nM [164] depending on the biochemical or cellular presentation of CD44v6, the data here 
confirms that the re-engineering of the Fab had nominal impact on the antigen-binding 
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specificity and affinity. Additionally, the cell binding assay demonstrated that the MKN74 
cell-based system is robust; thus, validating its utility for the NP binding assays. 
 
 
Figure 2. Approximate EC50 binding of the v6 Fab to a CD44v6-derived peptide (a) and 
cells (b). a) ELISA was used to determine the approximate EC50 binding of serially-diluted 
free (-) Fab and v6 Fab (highest Fab concentration = 500 nM) to a CD44v6-derived 
peptide [164]. FACS was used to determine the EC50 binding of serially-diluted v6 Fab to 
MKN74-CD44v6+, GP202 and MKN74. c) Negative controls of the cell binding assays 
with the three same cell lines as b) were similarly used to assess the binding profile of the 
negative control Fab at 500 nM ((-) Fab), anti-human-AlexaFluor555 secondary (2nd only) 
and unstained cells (cells only).  n=2 biochemical/biological replicates. Error bars 
represent the standard deviation. OD 450 nm = optical density at 450 nm. MFUs = mean 
fluorescence units. 
 
4.3. Manipulation of FluoSpheres® leads to extensive aggregation 
 Several attempts were made to conjugate the v6 Fab to the FluoSpheres® 
following the design outlined in Figure 1. The protocol detailed in section 3.5 required the 
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use of centrifugation to wash the FluoSpheres® in order to remove the unconjugated 
SM(PEG)24 linker and v6 Fab. The resulting preparations had very high Z-averages (size) 
and PdIs as well as negative zeta-potentials (Table 1). This was even seen in the 
negative control preparations where no linker and Fab were included. The high Z-
averages and PdIs indicate that the FluoSpheres® had extensive aggregation because an 
individual FluoSphere® itself has no possibility of increasing its 200 nm size. The slightly 
negative zeta-potential of the non-functionalized FluoSpheres® was also unexpected 
because they are modified with positively-charged amine groups. During commercial 
production, the FluoSpheres® begin as being carboxylated and are later amine-modified. 
Thus, a possible reason for the change in the charge is due to removal of some or all of 
the amine groups during the washing steps. 
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Table 1. Physicochemical properties of experimental FluoSpheres®. Attempts were made 
to conjugate the v6 Fab to the FluoSpheres® with the SM(PEG)24 crosslinker. Parallel 
studies eliminated the crosslinker to see the effect of Fab adsorption to the FluoSpheres®. 
FluoSpheres® only were straight from the stock without manipulation/washing. Z-average 
(size), polydispersity index (PdI) and zeta potential of the different FluoSphere® 
preparations. 10:1 and 1000:1 = # of Fab molecules per # of FluoSpheres®. (-) Fab = 
negative control Fab. v6 Fab = re-engineered AbD15179. ± represents the standard 
deviation of n=3 assay replicates. 
Crosslinker Ligand 
Z-average 
(size, nm) 
Polydispersity 
Index (PdI) 
Zeta potential 
(charge, mV) 
SM(PEG)24 
1000:1 v6 Fab 1157 ± 60 0.35 ± 0.01 -13.1 ± 1.1 
1000:1 (-) Fab 1527 ± 98 0.41 ± 0.05 -14.7 ± 0.8 
10:1 v6 Fab 1266 ± 163 0.38 ± 0.05 -14.7 ± 1.2 
10:1 (-) Fab 1527 ± 36 0.40 ± 0.02 -15.0 ± 0.7 
No Fab 1232 ± 47 0.37 ± 0.04 -3.0 ± 1.0 
no crosslinker 
1000:1 v6 Fab 1489 ± 135 0.43 ± 0.06 -14.0 ± 1.7 
1000:1 (-) Fab 1952 ± 123 0.80 ± 0.12 -16.7 ± 3.2 
10:1 v6 Fab 772 ± 62 0.50 ± 0.07 -16.4 ± 0.7 
10:1 (-) Fab 2921 ± 581 0.89 ± 0.19 -12.1 ± 3.1 
No Fab 1700 ± 232 0.90 ± 0.16 -12.3 ± 1.9 
FluoSpheres® only 733 ± 80 0.25 ± 0.01 8.1 ± 1.4 
 
 Even though the physicochemical data was disappointing, tests for specific binding 
to the experimental cells were still attempted. FACS demonstrated very high fluorescence 
values for the FluoSpheres® with the linker, but low values above background in the 
absence of the linker (Figure 3). A slight increase in binding was seen with FluoSpheres® 
that had 1000 molecules of adsorbed v6 Fab per FluoSphere® compared to controls. The 
extensive aggregation and near lack of CD44v6-specificity with the FluoSpheres® 
prompted the cessation of working with the FluoSpheres®, and the studies with the PLGA 
were initiated. 
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Figure 3. FluoSpheres® with or without the SM(PEG)24 crosslinker and with or without the 
v6 or (-) Fab were tested for binding to MKN74 cells expressing CD44v6 or not as 
measured by FACS. 10:1 and 1000:1 = # of Fab molecules per # of FluoSpheres®. No 
replicates were performed. MFUs = mean fluorescence units. 
 
4.4. CD44v6-targeted PLGA NP design  
 PLGA was used as the primary material for this study due to its favorable qualities 
in drug delivery [186, 187] such as biodegradability, biocompatibility, tunable sustained 
drug release, capacity to harbor a plethora of drug types from small molecules to (large) 
proteins [180, 183] and nucleic acids [181], the ability to protect the drug from 
degradation, malleable surface properties for further functionalization (e.g. tethering of 
targeting ligands) and FDA/EMA approval. FKR648, a fluorophore in the red spectrum, 
was chosen because the GFP expression of the cells would not interfere with NP 
detection. PEG was incorporated in the formulation to potentially serve as a stealth agent 
and/or for mucus penetration in potential in vivo characterization [188]. 5000 MW PEG 
was specifically chosen as it was shown to have maximal reduction in protein corona 
formation in PLA NPs [189]. The maleimide served as the functional group for covalent 
Fab conjugation via a thiol-Michael addition reaction [184]. Importantly, conjugating the C-
terminus of the Fab to the surface of the NPs via the maleimide helped to ensure that the 
Fab was oriented such that the N-terminal, antigen-binding domain was available for 
receptor (i.e. CD44v6) binding (Figure 4) [172]. 
CHAPTER IV 
66 
 
 
 
Figure 4. Schematic of v6 Fab-PLGA nanoparticle (NP) design. AbD15179 was re-
engineered to express three C-terminal cysteines (v6 Fab). The PLGA NPs were 
composed of 80% core PLGA, 10% PLGA-FKR648 and 10% PLGA-PEG-Maleimide and 
nanoprecipitated in 0.5% Pluronic F127 with or without paclitaxel loading (PTX). The v6 
Fab was mildly reduced with TCEP and added to the washed PLGA NPs to ultimately 
produce PLGA-based NPs that were fluorescent, PEGylated and decorated with a human 
Fab for targeting human CD44v6. 
 
 The NPs in this study were produced with the following components and 
percentages: 80% PLGA (50:50 LA:GA), 10% PLGA-FKR648 and 10% PLGA-PEG-
Maleimide. Nanoprecipitation, the primary method for encapsulation of hydrophobic drugs 
(e.g. PTX), was used for NP construction for its robust and facile protocol. Pluronic F127 
was chosen because this surfactant is cytocompatible, and drug-loaded, F127-coated 
PLGA NPs have higher cancer cell uptake and cell-killing ability and are able to overcome 
drug resistance [190]. Additional studies incorporated PTX during the production protocol 
as this served as a model drug and one that is prone to chemoresistance [176]. With the 
design of the NPs in place, it was then possible to proceed to the physical and biological 
characterization of the v6 Fab-PLGA NPs. 
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4.5. Physicochemical properties of v6 Fab-PLGA NPs 
 The physicochemical qualities of nanoparticles help to predict their in vivo 
behavior. The Z-average (hydrodynamic radius or size) of the PLGA NPs was measured 
at ~200-400 nm with a polydispersity index (PdI) ~0.2-0.4 and an overall negative zeta-
potential (charge) (Table 2), as measured by DLS and LDA. As expected, due to its 
hydrophobic character, the association efficiency of PTX was close to 100% [191]. The v6 
Fab-decorated NPs displayed an increase in Z-average and decrease in charge, helping 
to confirm the presence of the Fab on the NPs. Though, the much larger increase in Z-
average for the v6 Fab-PLGA NPs was not expected just based on the presence of the 
Fab; therefore, the increase may be due to some aggregation even though an additional 
peak was not observed in the DLS profile (data not shown). TEM imaging confirmed the 
characteristic spherical morphology of PLGA-based NPs with sizes in the range of 100-
300 nm (Figure 5). These data are in agreement with the DLS data as well as previous 
studies from our group [180]. 
 
Table 2. Physical characterization of the PLGA NPs. Z-average (size), polydispersity 
index (PdI) and Zeta-potential (charge) of the Fab-decorated and bare PLGA NPs from 
nanoprecipitation, with or without Paclitaxel (PTX) encapsulation, as measured by DLS 
and LDA. n=3 formulation replicates and ± = standard deviation. 
NPs PTX 
Z-average Polydispersity Zeta Potential Association 
(size, nm) Index (PdI) (charge, mV) Efficiency (%) 
v6 Fab-PLGA  
- 379 ± 48 0.40 ± 0.05 -19.9 ± 0.4 - 
+ 293 ± 15 0.32 ± 0.04 -20.0 ± 0.4 100 ± 1 
(-) Fab-PLGA  
- 234 ± 27 0.21 ± 0.04 -18.2 ± 2.0 - 
+ 234 ± 34 0.22 ± 0.06 -19.6 ± 0.1 100 ± 1 
bare PLGA  
- 205 ± 6 0.16 ± 0.01 -15.6 ± 0.8 - 
+ 217 ± 10 0.24 ± 0.03 -17.4 ± 0.1 100 ± 1 
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Figure 5. TEM images of the v6 Fab- (a and b) and bare (c and d) PLGA NPs. a and c = 
25,000X magnification (scale bar = 0.5 µm). b and d = 120,000X magnification (scale bar 
= 100 nm). The boxes in each of the 25,000X magnification correspond to the 120,000X 
magnification for each NP preparation. 
 
4.6. v6 Fab-PLGA NPs specifically bind to a human CD44v6-derived peptide and to 
the surface of cells expressing CD44v6 
 After determining that the v6 Fab-PLGA NPs displayed favorable physicochemical 
qualities, it was then necessary to investigate their specific binding to CD44v6 presented 
as a biochemical and on the surface of gastric/intestinal cancer cells. Figure 6 shows the 
various experiments implemented during the optimization phase of NP construction and 
specific binding to CD44v6. The main cell-based readout was NP binding to NaN3-fixed 
MKN74 cells expressing human CD44v6 as monitored by FACS. The use of NaN3 fixation 
and low temperature helped minimize surface receptor recycling. Also, special care was 
taken to ensure that the proper negative controls (i.e. (-) Fab-PLGA NPs and non-
expressing cell lines) were implemented. 
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Figure 6. Binding of v6 Fab-PLGA NP to CD44v6 presented on the surface of a cell (a-c) 
or as a peptide (d) by FACS and ELISA, respectively. a) 50 µg of Fab-decorated NPs 
were developed with different molar ratios of Fab:PLGA during conjugations and tested for 
binding to 105 fixed MKN74-CD44v6+ cells. b) 50, 10 and 2 µg of NPs at 1:25 Fab:PLGA 
ratio were tested for CD44v6+ cell binding. Non-expressing cells (MKN74) were used as a 
dosing control. c) 10 µg of the v6 Fab-PLGA NPs at 1:25 were pre-incubated with 10% v/v 
FBS. In parallel, the MKN74-CD44v6+ cells were pre-treated with free v6 Fab or the (-) 
Fab at 250 nM before incubation of the v6 Fab-PLGA NPs. d) 50 µg of Fab-decorated or 
bare PLGA-FKR648-PEG-Mal NPs were incubated in 96-well plates containing adsorbed 
CD44v6-derived peptide and detected with anti-human-HRP. n=3 replicates. Error bars 
represent the standard deviation. OD 450 nm = optical density at 450 nm. MFUs = mean 
fluorescence units. ns = P-value >0.05. * = P-value ≤0.05. *** = P-value ≤0.001. 
 
 During the initial optimization phase, different molar ratios of Fab:PLGA during Fab 
conjugation were investigated. 50 µg of v6 Fab-PLGA NPs with the highest amount of 
Fab:PLGA (1:25) had the strongest binding to CD44v6+ MKN74 cells, and decreasing the 
amount of Fab to PLGA resulted in reduced binding (Figure 6a). This suggests that a 
“crowding effect” from steric hindrance caused by too many tethered ligands was not 
reached. It must be noted that significant efforts during the optimization stages to 
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demonstrate CD44v6+ cell-specific binding with v6 Fab-PLGA NPs produced with 
polyvinyl alcohol (PVA) as the surfactant were unsuccessful, thus prompting the utilization 
of F127 (Figure 7). 
 
 
Figure 7. v6 Fab-PLGA NPs produced by nanoprecipitation into polyvinyl alcohol (PVA) 
do not specifically bind to MKN74-CD44v6+ cells. PLGA NPs were injected into 2% PVA, 
instead of 0.5% F127, during NP production. Subsequent washes and Fab conjugation 
methods were identical to those in the rest of this study. The PLGA NPs were then 
monitored for cell binding by FACS. n=3 formulation replicates. Error bars represent the 
standard deviation. MFUs = mean fluorescence units. ns = P-value >0.05. 
 
 Once it was determined that a Fab:PLGA ratio of 1:25 was sufficient, we tested 
three quantities of the NPs for cell binding (Figure 6b). The highest binding correlated 
with the highest quantity (50 µg), and signal intensity was dose dependent. Though, 50 µg 
of the negative control NPs had >50% fluorescent cells compared to cells only (data not 
shown). It is important to note that there was minimal, but some, binding of the bare and (-
) Fab-PLGA NPs to the cells with 10 µg indicating that a large window between positive 
and negative binding was achieved at this amount. Additionally, the v6 Fab-PLGA NPs 
had higher binding to the negative cell lines compared to the (-) Fab- and bare PLGA NPs 
at 50 µg, for reasons that are currently unknown. CD44v6-specificity of the v6 Fab-PLGA 
NPs was finally validated when pre-treatment of the cells with free v6 Fab, but not the (-) 
Fab, inhibited most of the v6 Fab-PLGA NP binding (Figure 6c). Complete binding 
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inhibition of the v6 Fab-PLGA NPs with 250 nM of free v6 Fab was not detected, possibly 
due to binding kinetics and/or incomplete receptor occupation. 
 The presence of a biomolecule/protein corona, a consequence of NP exposure to 
a biological environment, is known to potentially reduce/abolish specific targeting of 
ligand-decorated NPs [156]. Thus, we performed a simple experiment where the v6 Fab-
PLGA NPs were incubated with 10% (v/v) FBS for two hours prior to incubation with the 
MKN74-CD44v6+ cells (Figure 6c). There was no difference in binding in the FBS-treated 
NPs suggesting that they should retain their CD44v6 targeting capability in an in vivo 
setting. Binding may have been maintained due to the presence of the PEG chains, which 
are known to reduce protein corona formation from non-specific adsorption [189]. 
 Because 10 µg of NPs gave a large window of positive vs. negative binding and 50 
µg of control NPs had >50% fluorescent cells, we decided to use 10 µg of NPs for ~105 
cells for all subsequent NP characterization studies that involved cell binding. Even 
though NP binding to MKN74-CD44v6+ gave lower fluorescence values than GP202, we 
chose to use the MKN74 cell system to maintain a robust positive and negative cell-based 
system with identical backgrounds. As a final confirmation, the v6 Fab-PLGA NPs, and not 
the negative controls, showed strong binding to the CD44v6-derived peptide as 
determined by ELISA, thus validating the presence of the Fab on the NPs (Figure 6d). 
The ELISA and FACS data are in agreement with the previous Fab-only data (Figure 2). 
The cell binding optimization allowed for the subsequent biological and technological 
characterization to proceed. 
 
4.7. Impact of surfactants on the targeting of v6 Fab-PLGA NPs 
 The use of surfactants in PLGA NP production is critical in maintaining NP stability. 
Surfactants act by decreasing the interfacial tension between the components in a 
material system to increase such properties as miscibility and dispersion [192]. Although 
Menon et al. studied the impact of surfactants on the physical and biological properties of 
PLGA NPs [190], no studies until now have investigated the impact of surfactants on the 
specific targeting of ligand-decorated NPs.  
 To confirm that v6 Fab-PLGA NPs produced in PVA do not demonstrate specific 
binding to CD44v6-expressing cells while those produced in F127 do, a parallel study was 
performed studying those and two other common surfactants, sodium cholate (Na Chol) 
and Tween-80. The PLGA NPs, independent of the presence of a Fab or not, produced in 
2% Tween-80, 0.5% F127, or 2% PVA had Z-averages around 300-400 nm and 
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polydispersity indices (PdIs) around 0.3-0.4 (Table 3). However, the NPs produced in 1% 
Na Chol or without surfactant (water only) had Z-averages >1000 nm and PdIs >0.6. 
These high values were most likely a result of aggregation, and not on actual NP size, as 
the PLGA was observed to become more difficult to resuspend with each subsequent 
wash. In general, the presence of a Fab did not cause significant changes in the zeta 
potential. 
 
Table 3. The physicochemical properties of the PLGA NPs, with or without Fab 
conjugation, that were produced in different common surfactants as measured by dynamic 
light scattering and laser Doppler anemometry. ± = standard deviation of n=3 
formulations. 
Surfactant Ligand 
Z-average 
(size, nm) 
Polydispersity 
Index 
Zeta Potential 
(charge, mV) 
2% Tween-80 
v6 Fab 289 ± 23 0.35 ± 0.07 -10.9 ± 0.8 
(-) Fab 340 ± 17 0.33 ± 0.01 -11.0 ± 1.0 
none 385 ± 55 0.46 ± 0.07 -4.9 ± 1.7 
0.5% F127 
v6 Fab 373 ± 126 0.38 ± 0.08 -10.9 ± 1.1 
(-) Fab 487 ± 121 0.49 ± 0.07 -8.8 ± 2.1 
none 383 ± 34 0.38 ± 0.06 -6.5 ± 3.2 
2% PVA 
v6 Fab 472 ± 18 0.26 ± 0.06 -4.2 ± 0.1 
(-) Fab 373 ± 62 0.28 ± 0.01 -5.5 ± 0.8 
none 410 ± 21 0.24 ± 0.05 -4.3 ± 1.4 
1% Na Chol 
v6 Fab 1392 ± 495 0.74 ± 0.07 -13.5 ± 0.3 
(-) Fab 865 ± 161 0.65 ± 0.13 -12.5 ± 2.8 
none 926 ± 54 0.82 ± 0.10 -6.2 ± 1.2 
water 
v6 Fab 1244 ± 462 0.79 ± 0.15 -6.3 ± 1.2 
(-) Fab 1024 ± 262 0.69 ± 0.11 -5.2 ± 1.1 
none 2282 ± 1163 0.77 ± 0.20 -2.8 ± 0.6 
 
 
 Enzyme-linked immunosorbent assay (ELISA) was used to monitor the presence 
of the Fab on the surface of the NPs (Figure 8a). All the tested formulations demonstrated 
nearly equivalent amounts of Fab where appropriate. However, Fab-conjugated NPs 
produced in 2% PVA had significantly reduced detection of the Fab, most likely a result of 
the PVA blocking maleimide accessibility to the Fab. 
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Figure 8. a) Fab presence on PLGA NPs produced in different common surfactants as 
measured by ELISA. b) Target cell binding of the Fab-conjugated PLGA NPs as 
measured by FACS. OD 450 nm = optical density at 450 nm and MFUs = mean 
fluorescence units. Error bars represent the standard deviation of n=3 formulations.  
 
 Overall, the v6 Fab-PLGA NPs had nominal binding to the non-expressing MKN74 
cells, except for some slight binding seen with the NPs produced in 1% Na Chol (Figure 
8b). Additionally, all the negative control NPs had nominal binding to the MKN74-
CD44v6+ cells. v6 Fab-PLGA NPs produced in 2% Tween-80 had the highest binding to 
the MKN74-CD44v6+ cells, while the lowest binding was seen with NPs produced in PVA 
or water only. It is important to note that the presence of the Fab on the NPs did not 
preclude receptor recognition, as seen with the NPs produced in water. Similarly, a large 
Z-average did not preclude a lack of cell binding, as seen with the NPs produced in 1% 
Na Chol. Even though Fab levels were comparable, except for PVA, the varied cell 
binding levels could be attributed to a possible impact that the surfactant remaining on the 
NPs may have on the Fab itself (e.g. altered structure, orientation and/or affinity) or on the 
availability of the Fab to the receptor (e.g. steric hindrance). 
 Although the v6 Fab-PLGA NPs produced in 1% Na Chol had higher binding to the 
positive cells than 0.5% F127, their non-specific binding to the negative cells and the large 
Z-averages disqualified them from further inquiry. Thus, the NPs produced in Tween-80 
and F127 were further tested to monitor the effect that surfactant concentration has on the 
same properties as seen in the initial experiments. 
 The concentration of the surfactant used during production, and ultimately the 
amount on the NP surface, may alter downstream target recognition. Therefore, the 
studies were repeated with Tween-80 and F127 at 2% and 0.5%. Physicochemical 
characterization demonstrated that the NPs had Z-averages around 250-400 nm, PdIs 
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around 0.25-0.40 (Table 4) and Zeta potentials around -10 to -20 mV. Surfactant 
percentage had no discernible effect on any of the above qualities. 
 
Table 4. The physicochemical properties of the PLGA NPs, with or without Fab 
conjugation, that were produced in Tween-80 or F127 at 2% or 0.5% as measured by 
dynamic light scattering and laser Doppler anemometry. ± = standard deviation of n=3 
formulations. 
Surfactant Ligand 
Z-average 
(size, nm) 
Polydispersity 
Index 
Zeta Potential 
(charge, mV) 
2% Tween-80 
v6 Fab 322 ± 20 0.28 ± 0.05 -11.1 ± 3.4 
(-) Fab 297 ± 11 0.24 ± 0.01 -16.4 ± 1.3 
none 334 ± 11 0.33 ± 0.02 -15.8 ± 0.7 
0.5% Tween-80 
v6 Fab 282 ± 59 0.32 ± 0.07 -14.1 ± 3.3 
(-) Fab 284 ± 24 0.26 ± 0.02 -18.4 ± 2.4 
none 377 ± 41 0.38 ± 0.01 -20.3 ± 0.6 
2% F127 
v6 Fab 278 ± 58 0.31 ± 0.10 -17.8 ± 0.6 
(-) Fab 341 ± 49 0.36 ± 0.05 -13.8 ± 2.8 
none 394 ± 56 0.34 ± 0.02 -11.3 ± 0.3 
0.5% F127 
v6 Fab 349 ± 80 0.34 ± 0.04 -11.5 ± 0.8 
(-) Fab 250 ± 70 0.27 ± 0.05 -11.7 ± 0.9 
none 240 ± 18 0.30 ± 0.03 -10.8 ± 0.7 
 
 ELISA again demonstrated the presence of the Fabs on the appropriate NPs 
(Figure 9a). No difference in Fab presence was observed between the two surfactants or 
concentrations. 
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Figure 9. (a) Fab presence on PLGA NPs produced in Tween-80 or F127 at 2% or 0.5% 
as measured by ELISA. (b) Target cell binding of the Fab-conjugated PLGA NPs as 
measured by FACS. OD 450 nm = optical density at 450 nm and MFUs = mean 
fluorescence units. Error bars represent the standard deviation of n=3 formulations.  
 
 Cell binding studies demonstrated similar non-binding of the v6 Fab-PLGA NPs on 
the negative cells as well as the negative control NPs on the positive cells (Figure 9b). 
The two formulations produced in Tween-80 had binding values in between those of F127, 
but there was no statistical difference between the two concentrations. The highest target 
binding was seen with the NPs produced in 2% F127 while the lowest was with 0.5% 
F127. The cause of this difference is unknown, but it may be due to the PEG molecules of 
F127 acquiring different orientations leading to hindrance or promotion of the proper 
orientation of the Fab [193]. 
 When compared with the initial study with the four surfactants, the NPs were 
slightly smaller and with lower Zeta potentials. This may have been due to the more mild 
washing conditions that incorporated Amicon filters and lower centrifugation speeds. 
These values coincide with the previous results (Table 1). Regardless, the cell binding 
results of the 2% Tween-80 and 0.5% F127 NPs agree with the initial study. The majority 
of the experiments performed were with v6 Fab-PLGA NPs that were produced in 0.5% 
F127. If this surfactant study had been performed prior to those other experiments, 2% 
F127 would have been used. 
 
4.8. v6 Fab-PLGA NPs demonstrate specific live cell binding and internalization 
 To ensure that the NPs still maintained CD44v6 specificity in live cells, the binding 
assays were repeated with MKN74 cells in culture with similar amounts of NPs and cell 
counts. The microscopy images demonstrate specific binding of the v6 Fab-PLGA NPs to 
CHAPTER IV 
76 
 
MKN74-CD44v6+ cells, and there was no detectable fluorescence of the bare PLGA NPs 
to either cell line (Figure 10a). Additionally, some of the NPs appear to have been 
internalized; though, the majority appears to be associated with the cell surface (Figure 
10b). The FACS results mostly correspond with the NaN3-fixed cells in that there was 
higher binding of the v6 Fab-PLGA NPs to the MKN74-CD44v6+ cells compared to the 
negative control NPs (Figure 10c). Although the overall fluorescence for the v6 Fab-
PLGA NPs was similar to that of the fixed cells, there is more fluorescence seen for the 
negative control NPs. This was not unexpected as live cells normally take up NPs in a 
dose dependent manner. Also, the use of trypsin during the cell detachment probably 
removed any NPs associated with the surface that had yet to be internalized. 
 
 
Figure 10. v6 Fab-PLGA NP binding to live cells as detected by light microscopy (a-b) 
and FACS (c). For both assays, live MKN74-CD44v6+ (and MKN74 for microscopy) cells 
were incubated with 10 µg of either v6 Fab- or bare PLGA NPs for 6 hrs. For the 
microscopy assay, the cells were fixed, actin-stained with phalloidin-AlexaFluor 546 
(Phalloidin-A546) and imaged by confocal light microscopy. a) 20X magnification and 
maximal projection images. b) shows the MKN74-CD44v6+ cells incubated with the v6 
Fab-PLGA NPs at 63X magnification (corresponding to the white box in the upper right 
panel of a)). The upper panel shows the maximal projection while the lower panel shows 
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an interior Z-dimension plane. c) MKN74-CD44v6+ cells were detached with trypsin 
before FACS measurement. Scale bar = 50 μM. n=3 replicates. Error bars represent the 
standard deviation. MFUs = mean fluorescence units. *** = P-value ≤0.001. 
 
4.9. v6 Fab-PLGA NPs demonstrate nominal cytotoxicity but not target-specific 
drug delivery 
 In order to understand the cytotoxicity of the v6 Fab-PLGA NPs with and without 
PTX encapsulation, we measured cell viability with the MTT reduction assay (Figure 11). 
The 6 hr NP incubation was chosen to simulate the estimated in vivo exposure time, and 
the additional time (18 or 42 hr) was needed to monitor the antimitotic effects of the PTX. 
The 24 hr time point (without treatment removal) was chosen to simulate more long-term 
exposure of residual NPs. The empty NPs, independent of Fab decoration, were not 
cytotoxic to the MKN74 (+/- CD44v6) cells and only slightly toxic to the GP202 cells. At the 
6+18 hr time point, no cytotoxicity was observed for any of the cells when exposed to the 
PTX-loaded NPs. Though, more cytotoxicity was observed in the 24 hr and 6+42 hr time 
points for the MKN74 (+/- CD44v6) cells (~40-60% viability) than for the GP202 cells 
(~80% viability). This loss of viability was similar to free PTX at equivalent PTX 
concentrations. This was probably due to PTX release into the media when incubated with 
the cells or previously during storage[194] and not an effect caused by intracellular 
delivery. Overall, the empty NPs are not cytotoxic, but NP association did not alter the 
toxicity of PTX. 
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Figure 11. Cytotoxicity of empty PLGA NPs and Paclitaxel (PTX)-loaded PLGA NPs. 
MKN74, MKN74-CD44v6+ and GP202 cells in 96-well format were incubated with 50 or 5 
µg/mL of empty PLGA NPs (no PTX) or PTX-loaded PLGA NPs (+ PTX) with or without 
(bare) decoration of the v6 Fab or (-) Fab for 24 hrs total (24) or for 6 hrs followed by NP 
removal and recovery in fresh media for an additional 18 hrs (6+18) or 42 hrs (6+42) 
before determining cell viability by MTT reduction. Free PTX was used as a control for 
cytotoxicity and for the PTX-loaded NPs. The levels of PTX in 50 and 5 µg/mL of PTX-
loaded NPs was equivalent to 10 and 1 µg/mL of free PTX, respectively. n=6 formulation 
replicates. Error bars represent the standard deviation.  
 
4.10. v6 Fab-PLGA NPs maintain CD44v6-specific binding when produced by w/o/w 
double emulsion 
 PLGA NPs can be produced with a handful of methods depending on the type of 
(bio)molecule (e.g. hydrophobic vs. hydrophilic) used for nanoencapsulation [186, 187]. 
The principle method of NP production in this study was nanoprecipitation by injection of 
the PLGA components dissolved in an organic solvent into water containing 0.5% F127. 
Here, we aimed to expand the therapeutic/diagnostic potential of our system to be able to 
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encapsulate hydrophilic molecules such as biopharmaceuticals. Thus, water-in-oil-in-
water (w/o/w) double emulsion with an identical Fab conjugation protocol was employed to 
produce similar NPs [180]. DLS and LDA demonstrated that the NPs have similar physical 
profiles as those produced by nanoprecipitation (Table 1). Importantly, they retained 
similar cell binding specificity (Figure 12). 
 
 
Figure 12. v6 Fab-PLGA NPs produced by w/o/w double emulsion demonstrate CD44v6+ 
cell-specific binding. 10 µg of PLGA NPs produced by w/o/w double emulsion and the 
standard Fab conjugation protocol were monitored for binding to MKN74-CD44v6+ or 
MKN74 cells by FACS. n=3 replicates. Error bars represent the standard deviation. MFUs 
= mean fluorescence units. *** = P-value ≤0.001. 
 
4.11. v6 Fab-PLGA NPs resist simulated intestinal fluid (SIF) exposure 
 One possible application for the v6 Fab-PLGA NPs is in vivo diagnosis of 
CD44v6+ (pre-) metastatic CRC [21, 195] by oral administration. To determine whether 
the v6 Fab-PLGA NPs could withstand the intestinal environment, the NPs were exposed 
to SIF (pH 6.8), with or without the presence of pancreatin, for 15 or 60 min (Figure 13). 
No difference in cell binding was seen when compared to PBS-only treatment. However, 
binding was completely abolished when pancreatin was present in the SIF. This is not 
unexpected as the pancreatin most likely enzymatically degraded, at the very least, the v6 
Fab on the surface of the NPs, and probably the PLGA itself, similar to that observed in 
PLA NPs [196]. Perhaps the NPs could be protected in vivo by inhibiting the intestinal 
enzymes with protease inhibitors or pH decrease [174] and/or through encapsulation 
within microparticles [57]. 
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Figure 13. v6 Fab-PLGA NPs exposed to simulated intestinal fluid (SIF) maintain 
CD44v6+ cell binding. v6 Fab-PLGA NPs were exposed to SIF at pH 6.8 with or without 
pancreatin (panc) for 15 or 60 min and cell binding was monitored by FACS. n=3 
replicates. Error bars represent the standard deviation. MFUs = mean fluorescence units. 
ns = P-value >0.05. *** = P-value ≤0.001. 
 
4.12. v6 Fab-PLGA NPs resist longer-term storage and cryopreservation 
 One disadvantage of antibody-based therapy and in vivo diagnostics is the 
frequent need for maintaining cold chain storage. This imposes storage and distribution 
costs at all stages from post-production to the patient. Antibody-decorated NPs, like those 
developed here, are also constrained to the same limitations. As polymeric nanoparticles, 
such as those developed herein, are able to be cryopreserved [197], we aimed to 
superficially assess different storage conditions of the v6 Fab-PLGA NPs. We also aimed 
to translate our stability studies of freeze-dried biotherapeutics (e.g. insulin [183] or a 
therapeutic mAb [180]) encapsulated within PLGA NPs to PLGA NPs with antibodies on 
their surface.  
 Parallel studies investigated the effect of mid-range storage times in solution at 4 
°C and cryopreservation with two weeks of storage at different temperatures on the v6 
Fab-PLGA NP. During the in solution study, NPs were maintained at 1 mg/mL in water. 
Decreased binding occurred as time progressed, but a plateau was reached after 2-3 
weeks (Figure 14a). During the cryopreservation study, the NPs were diluted to ~15 
µg/mL in water with or without 10% trehalose, freeze-dried, and stored at -20 °C, 4 °C or 
RT for two weeks. The NPs were then rinsed with water before biological assessment by 
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FACS. NPs freeze-dried without trehalose had nominal cell binding (Figure 14b); though, 
it should be noted that, unexpectedly, no PLGA pellet was observed upon reconstitution 
and centrifugation. Importantly, the freeze-drying process did not significantly reduce cell 
binding when the NPs were stored at -20 °C or 4 °C but did reduce binding when the NPs 
were stored at RT. 
 
 
Figure 14. Effect of storage conditions on CD44v6+ cell binding of v6 Fab-PLGA NPs. a) 
Binding of v6 Fab-PLGA NPs stored in solution (water) to MKN74-CD44v6+ cells over 
time. b) In a parallel study, v6 Fab-PLGA NPs were freeze-dried with or without 10% 
trehalose (treh) and stored at -20 °C, 4 °C or room temperature (RT) for two weeks. n=3 
formulation replicates. Error bars represent the standard deviation. MFUs = mean 
fluorescence units. ns = P-value >0.05. ** = P-value ≤0.01. *** = P-value ≤0.001. 
 
 Overall, these results suggest that freeze-drying NPs decorated with antibodies on 
their surface is a viable storage strategy similar to freeze-drying antibodies within NPs 
[180]. The possible explanations for the reduction in binding as storage temperature 
increased has to do with the structural integrity of either the Fab, the PLGA NPs, the 
covalent linkage of the Fab to the NPs, or any combination of the three. With these 
specific NPs, freeze-drying may be unnecessary as the highest binding was observed with 
NPs that were maintained at a high concentration in solution at 4 °C. Though, it should be 
considered that freeze-drying may help prevent bacterial contamination and/or 
aggregation common when biotherapeutics are stored in solution. It may also prevent 
premature release of an encapsulated drug and/or degradation of the material. Freeze-
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drying can potentially allow for the NPs to be formulated within a pill for oral delivery or 
within a biosensor/lateral flow assay. 
 Only found one study was found that employed freeze-drying to (PLGA) NPs 
decorated with an antibody, but targeting was not evaluated neither before or after [198]. 
As the novelty and clinical impact of cryopreservation of antibody-decorated NPs is high, it 
is hoped this preliminary data sparks further investigation. Regardless, these results 
further verify our previous studies with nanoencapsulated biotherapeutics [180, 183]. 
 In summary, the v6 Fab-PLGA NPs developed herein demonstrate valuable 
physical, biological and technological characteristics. They have morphology, size, PdI 
and charge typical of most PLGA-based NPs. The negative charge especially aids in 
reducing non-specific cell binding. Biologically, the v6 Fab-PLGA NPs bind specifically to 
CD44v6 when presented as a peptide and on the surface of cells. Importantly, they have 
nominal binding to cells that do not express CD44v6. The live cell binding studies also 
show that the NPs can be internalized in CD44v6-expressing cells. They are not cytotoxic 
and withstand SIF exposure but not in the presence of pancreatin. Technologically, the v6 
Fab-PLGA NPs can be produced by nanoprecipitation and w/o/w double emulsion to 
harbor either hydrophobic or hydrophilic drugs, respectively, and they retain CD44v6 
targeting after cryopreservation and short term storage in the cold. 
 
5. Conclusions 
 The v6 Fab-PLGA NPs display many favorable qualities as a potential CD44v6-
targeted drug and/or diagnostic delivery agent. The NPs were designed with immediate 
administration into humans in mind. As they are non-toxic, decorated with a fully human 
antibody fragment and the functional material (PLGA) is approved by the FDA/EMA, we 
would expect nominal issues (e.g. immunogenicity) in humans. Their PEGylation status 
also confers them with added “stealth” qualities to minimize phagocytic recognition for 
enhanced circulation times or, alternatively, for mucus penetration in the gastro-intestinal 
administration. Additionally, the NPs bind CD44v6+ cells in the presence of serum; 
therefore, it is expected that they would maintain CD44v6 targeting in circulation. 
Oral/rectal administration is possible, but inclusion of enzyme inhibitors would be needed 
to minimize damage to the NPs. Independent of the route of administration, the resistance 
of the v6 Fab-PLGA NPs to cryopreservation, and that trehalose is a widely-used 
excipient [199], suggests that they could be resuspended on demand or possibly 
incorporated within a pill/capsule. In their current state as fluorescent NPs, they can be 
CHAPTER IV 
83 
 
used mainly in diagnostics to target CD44v6-expressing tumors such as HNSCC tumors 
for which the Fab was originally developed [40]. However, they have the capacity to 
harbor hydrophobic or hydrophilic drugs depending on the production method, and, as 
such, could act in theranostics as well. Importantly, the core materials of the nanosystem 
developed herein (PLGA + fluorophore + maleimide functional groups) allow for tethering 
of the whole range of targeting ligands from peptides, proteins, nucleic acids, small 
molecules and, of course, other antibodies. 
 Given the many roles of CD44v6 in (metastatic) carcinoma, we envision the v6 
Fab-PLGA NPs possibly targeting CSCs within the tumor [21] or that have escaped into 
circulation [27]. These NPs can potentially be used as an in vivo diagnostic from 
parenteral or oral/rectal administration. It may also be possible to incorporate these NPs 
within a biosensor [145] to detect CD44v6-expressing cells ex vivo (e.g. liquid biopsy). 
The epitope that the Fab was developed against [164] corresponds to the interaction 
region between CD44v6 and c-Met/VEGFR-2 [200], but the Fab itself has not been tested 
for its ability to disrupt this interaction or inhibit HGF/VEGF signaling, similar to anti-
CD44v6 antibodies [10] or a five amino acid peptide derived from CD44v6 [12, 36, 37]. 
Thus, it may be possible for the v6 Fab-PLGA NPs to act synergistically with the Fab in a 
therapeutic context, similar to some ADCs [172], by inhibiting the above receptor 
interaction/ligand binding and delivering a therapeutic payload. Although the speculations 
above require experimental proof, the NPs developed herein present clinical potential and 
provide a launching point for future improvements and therapeutic and/or diagnostic 
opportunities. 
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Concluding remarks and future perspectives 
  
CHAPTER V 
85 
 
1. Concluding remarks 
 Variant isoforms of CD44 expressing the v6 exon (CD44v6) are well-studied, cell 
surface, transmembrane glycoproteins that have a role in several of the malignant 
processes associated with cancers of the epithelium, thus making CD44v6 a potential 
target for therapy and/or diagnosis. Exploiting combined targeted drug delivery and 
nanomedicine represents a viable strategy in detecting CD44v6 expression in human 
tumors. Focusing on materials and ligands that are human compatible, while maintaining 
novelty, helps refine biomedical engineering design parameters. Targeting ligands based 
on recombinant monoclonal antibodies and aptamers each have the potential for low 
immunogenicity and high target specificity and affinity as well as other advantages and 
disadvantages. Taking all this into consideration, ligand-decorated nanocarriers that target 
CD44v6-expressing cells that simultaneously bypass normal cells could be a good tool in 
the oncology clinic. 
 The two main objectives of this thesis were to identify and characterize a novel 
ligand specific to human CD44v6 and to develop and characterize a polymeric nanocarrier 
that targets human CD44v6 for delivery of a drug and/or diagnostic. Ideally, the novel 
ligand identified in the first aim would then be used as the targeting ligand to be tethered 
to the nanocarrier.  
 RNA aptamers were chosen as the novel anti-human CD44v6 ligand type because 
there were none found in the literature or in the patent landscape, and they provided an 
opportunity to explore an emerging molecular recognition technology. The experimental 
design behind the selection process (i.e. SELEX) was based on the tools available (e.g. 
CD44v6-derived peptide and the CD44v6-overexpressing cells) and on the successful 
identification of the anti-CD44v6 Fab, AbD15179. Once overcoming initial technical 
hurdles, the procedures for the peptide and cell SELEX were straight forward, and quality 
control gels suggested that aptamer retrieval and subsequent amplification were 
successful. Due to the nature of classical SELEX (i.e. without deep sequencing), it was 
necessary to perform many rounds of SELEX before determining whether CD44v6-
specific aptamers were being enriched.  
 CD44v6 enrichment was not demonstrated when fluorescently labeled polyclonal 
aptamers from the peptide SELEX outputs were tested for binding to CD44v6-derived 
peptide or CD44v6-expressing cells. It is possible that there were some technical issues 
(e.g. improper aptamer labeling or aptamer quantities) leading to this conclusion. 
However, when the binding assay exploiting AbD15179 as a positive control failed, the 
validity of the capture step of the peptide SELEX was placed under serious doubt and 
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undermined the resulting outputs. In hindsight, this control assay should have been 
performed before the peptide SELEX procedure was implemented. Although, deep 
sequencing and bioinformatics (e.g. APTANI) could elucidate sequence enrichment, but 
only synthesis and characterization of enriched monoclonal sequences would verify 
whether the SELEX protocols identified CD44v6-specific RNA aptamers or not.  
 AbD15179 was used as a known targeting ligand for nanocarrier funtionalization 
during parallel proof-of-concept studies while the identification of an anti-CD44v6 RNA 
aptamer was under investigation. The re-engineering of AbD15179 to express three C-
terminal cysteines did not affect the binding affinity to the CD44v6-derived peptide or the 
CD44v6-expressing cells compared to the original Fab as seen in the Nestor group 
studies; thus allowing us to proceed with the Fab-decorated nanocarrier studies. 
 Initial nanocarrier studies utilized fluorescent, amine-modified, polystyrene latex 
FluoSpheres® because of their fluorescence, defined size and surface properties. Here, 
the idea was to conjugate the Fab to the FluoSpheres® using a maleimide-based linker 
containing 24 PEG chains (SMPEG24). Unfortunately, the FluoSpheres® proved to be 
difficult to work with due to their large tendency to aggregate and not dissociate during the 
washing steps. These issues are assumed to be the main reason why no specific binding 
was observed on the CD44v6-expressing cells. After exhaustive efforts to address the 
aggregation problems failed, similar design strategies were implemented with polymeric 
(i.e. PLGA-based) nanoparticles (NPs). 
 PLGA was chosen as the polymeric nanomaterial due to its many favorable 
properties in drug/diagnostic delivery in humans and because of the expertise within the 
Nanomedicines and Translational Drug Delivery group at i3S. PLGA NPs now 
incorporated PEG and maleimide directly into production bypassing the need for a linker. 
They were produced by nanoprecipitation within a 2% PVA solution as the surfactant. 
Different molar ratios of Fab to PLGA were also investigated. All attempts to demonstrate 
specific binding of v6 Fab-decorated NPs developed using this strategy failed. 
 It was only when the v6 Fab-decorated PLGA-FKR648-PEG-Mal NPs were 
produced in Pluronic F127 did they achieve specific binding to the CD44v6-expressing 
cells. Once this was demonstrated and reproduced, further optimization and 
characterization of the v6 Fab-PLGA NPs could progress. These NPs demonstrated 
expected sizes of 200-300 nm, negative zeta-potential and spherical morphology. 
Because a plateau of cell binding was not reached when investigating the molar ratio of 
Fab:PLGA, it is probable that more Fab may be able to be conjugated to the NPs resulting 
in even higher binding values. Because this novel nanosystem maintains targeting in the 
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presence of serum, is composed of an approved material (i.e. PLGA) and contains a fully 
human Fab, it is expected that it would be well tolerated in humans. The mid-term storage 
study suggests that the NPs could be stable for longer term storage in solution, but the 
cryopreservation study is more interesting. Cryopreserved NPs maintained cell targeting 
but was reduced with increasing storage temperature. Most likely this is due to 
degradation and/or instability of the Fab that could have been caused by 
impurities/contamination in either the Fab or the trehalose or only because of temperature.  
 The change in surfactant from PVA to F127 prompted the focused study of 
investigating the impact that common surfactants and their concentration have on 
downstream target recognition. The results confirmed that v6 Fab-decorated NPs 
produced in 2% PVA do not bind to the CD44v6-expressing cells. This study also 
demonstrated that the 0.5% F127 that was used during the production of the v6 Fab-
PLGA NPs for the majority of the experiments in Chapter IV was not ideal.  
 Reviewing the objective of targeting cells expressing CD44v6, it is important to 
step back and re-evaluate the relevancy of CD44v6 as a target. The lack of specific 
isoform (e.g. CD44v3-v10) and/or glycoform targeting leading to targeting of multiple 
proteins could be a hurdle. Within a given cancer origin, there may be more than one v6 
exon-expressing isoform with different functions. In the context of CRC, the study from 
Todaro et al. is pretty convincing where they show the role of the tumor 
micronenvironment in the re-education of CD44v6- progenitor cells into cancer stem cells 
leading to increased metastasis. However, low expression of CD44v6 in the normal crypt 
stem cell population of the stomach and intestine may be problematic in both diagnosis 
and therapy. The biggest reason for hesitation to target CD44v6 in drug delivery is the 
probable skin toxicity due to keratinocyte expression as evidenced in the phase I clinical 
trials with bivatuzumab mertansine; yet, this may be reduced by non-parenteral routes of 
administration. Though, CD44v6 may be best served in targeted therapy due to its role as 
an RTK co-receptor. Similar to the CD44v6-derived five amino acid peptide that blocks the 
c-Met-mediated signaling, AbD15179 could behave similarly since the binding epitope 
overlaps with that of the peptide. Additionally, the diagnostic value of CD44v6 still 
remains. The work of da Cunha et al. clearly shows the increasing expression of CD44v6 
in GC as malignancy increases, and the original purpose of AbD15179 was in the in vivo 
radiolabeling of HNSCC. Given the above conclusions, the nanosystem developed herein 
may be best utilized in its current form as a vehicle to deliver a diagnostic agent or 
AbD15179 itself and not necessarily as a drug delivery agent. 
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 Overall, the thesis-related research achieved one of the two goals. A novel ligand 
that is specific to human CD44v6 was not identified. The second aim of developing a 
human compatible, polymeric nanocarrier that targets human CD44v6 was achieved. In 
their present form, the v6 Fab-PLGA NPs demonstrated favorable physicochemical, 
biological and technological qualities that allow them to potentially be used in the oncology 
clinic as an (in vivo) diagnostic tool. Though, their use in drug delivery requires further 
investigation and optimization. 
 
2. Future perspectives 
 As with most scientific and technological advancements, improvements in, and 
applications of, this research could definitely be explored. In the case of the anti-CD44v6 
RNA aptamer identification, all of the outputs from each round of both peptide and cell 
SELEX are still available. None of the cell SELEX outputs were tested for enrichment; 
therefore, one could fluorescently label, for example, rounds 0, 4 and 7 and see if there is 
increased binding to the peptide or cells as was done for the peptide SELEX outputs. 
Alternatively, one could perform the deep sequencing and bioinformatics on some of the 
outputs and synthesize and characterize some of the promising sequences, as stated 
previously. Because the tools (peptide and cells) are robust and available, the SELEX 
protocols could be repeated with some adjustments. Specifically, the cell SELEX protocol 
should incorporate total elution from the v6-expressing cells in the first few rounds before 
performing the antibody elution in later rounds. This would help to maintain more diversity 
in the beginning of the SELEX and allow for more possible clones to be eluted during the 
antibody competing rounds. The capture step of the peptide SELEX quality control assay 
failed to demonstrate AbD15179 binding, and plate/plastic-based ELISA works well to 
demonstrate AbD15179 binding to the peptide. Therefore, adsorbing the peptide to plastic 
to capture the CD44v6-specific aptamers could replace the in solution-based approach to 
aptamer-peptide capture with magnetic beads. Lastly, if an anti-CD44v6 aptamer is 
identified, it could be used to decorate nanoparticles as was originally intended or possibly 
as therapeutic agent on its own. With that in mind, it should be noted that AbD15179 may 
also act as a therapeutic as it recognizes an epitope that is associated with the c-Met 
interaction and may function similarly as the five amino-acid currently under clinical trials. 
 The weaknesses of the targeted nanosystem, lack of evidence of specific drug (i.e. 
paclitaxel) delivery to CD44v6-expressing cells and in vivo studies, should be addressed 
first. In the case of the drug delivery studies, shorter conjugation times and/or the use of 
cryopreservation could minimize the presumed premature release of the drug during 
CHAPTER V 
89 
 
storage prior to addition to the cells. Alternatively, drugs with different chemical and/or 
biological properties could be explored, because the v6 Fab-PLGA NPs can be used to 
encapsulate hydrophobic or hydrophilic drugs. As an example in translating other similar 
work, a monoclonal antibody could be encapsulated in the v6 Fab-PLGA NPs for localized 
and sustained release in the presence of a CD44v6-expressing tumor but outside the cell 
or could be for intracellular delivery as a signaling pathway disruptor or to engage TRIM21 
for directed degradation.  
 In vivo studies could initially focus on tumor models and essentially replicate the in 
vitro cell-based studies but in rodents. Because the v6 Fab-PLGA NPs are fluorescent 
with FKR648, systemically-delivered NP targeting could be monitored in SCID mice 
harboring MKN74 tumors with or without CD44v6 overexpression in real time. 
Independent of whether or not the in vitro drug delivery assays demonstrate CD44v6-
expressing cell cytotoxicity, drug-encapsulated NPs could also be delivered systemically 
and tumor volume could be assessed in the same in vivo tumor model. This could also 
open up the possibility for a theranostic approach where the same NPs could treat the 
tumor and monitor its progression at the same time. Of course, rodent studies would need 
to be highly convincing before proceeding to non-human primates or humans. 
 A possible application of the v6 Fab-PLGA NPs is to diagnose gastric or colorectal 
cancer from oral, and not systemic, administration. That is why the simulated intestinal 
fluid studies were performed. Though, several hurdles would need to be addressed before 
embarking on these studies. First, an appropriate model where the tumor cells are 
orthotopically implanted or derived from chemical or genetic manipulation needs to be 
established such that the GI tract tumor has a chance of being reached from the luminal 
side. Second, the optimal mucopenetrating ability of the NPs should be established in vitro 
by empirically adjusting the amount and/or MW of the PEG chains. Lastly, the NPs would 
need to be protected from the low pH and enzymes of the stomach through pre-
preparation of the GI environment or through microencapsulation of the NPs. Once these 
are established, the NPs could be administered by oral gavage and monitored for tumor 
recognition and biodistribution. 
 Longer term storage in solution studies could also be implemented. At the same 
time, the release profile of the encapsulating drug as well as any dissociation of the Fab 
should be investigated in parallel. More importantly, the cryopreservation of the NPs 
should be more thoroughly studied. The use of different amounts of trehalose and 
cryopreservants as well as optimizing the steps of the lyophilization process could be 
tested following the studies of Pedro Fonte and colleagues. Ideally, a formulation would 
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be achieved where the NPs could be stored at room temperature. In this state, it is 
envisioned that the NPs could be incorporated within a pill/capsule or within a powder 
meant for inhalation. 
 As the nanosystem developed here was produced in microgram quantities at a 
time, it is important to investigate the scaling up of the system. This would be informative 
for providing sufficient quantities for in vivo studies, both pre-clinical and clinical. For 
example, a microfluidizer could be incorporated to automate the nanoprecipitation, NP 
washing and downstream Fab conjugation and purification. 
 The nanosystem developed herein should also be considered as being modular. 
Because these NPs are functionalized with maleimide, it is possible to conjugate other 
thiol-bearing ligand types (e.g. aptamers, proteins or peptides) or other antibodies or 
fragments against different targets (e.g. stromal cell-related targets) to the NPs, bearing in 
mind a proper site-oriented bioconjugation protocol. Also, these NPs are able to be 
produced to harbor hydrophobic or hydrophilic drugs. Alternatively, other maleimide-
modified nanomaterials (e.g. liposomes) may be used with the engineered v6 Fab. 
 The work developed in this thesis laid a solid foundation for future exploration as 
outlined above. The identification of novel anti-CD44v6 aptamers should be revisited to 
bypass the licensing restrictions of AbD15179 and to provide a competing, and possibly 
better, molecular recognition technology to that of antibodies. Due to the limitations of the 
nanomaterial and CD44v6 as a relevant/safe target, the drug delivery potential of the 
nanosystem should be re-evaluated, and more focus should be placed on in vivo 
diagnosis with different modes of administration. Finally, the v6 nanosystem combined 
with the cell-based tools should be used as a model to investigate technological aspects 
of targeted NP development akin to the surfactant and cryopreservation studies.[201] 
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